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RESUMO 
 
Introdução: O carcinoma de células renais (CCR) é caracterizado por um fenótipo 
glicolítico (“efeito de Warburg”) com aumento da produção de lactato. Este tem um papel 
importante na biologia tumoral e na modulação do microambiente. Recentemente, o lactato 
tem sido descrito como modelador dos mecanismos epigenéticos, levando à inibição da 
atividade das histonas desacetilases. Assim, aprofundar o conhecimento que temos sobre 
o papel do lactato na regulação do epigenoma de tumores com elevada taxa glicolítica 
pode levar à descoberta de novas estratégias terapêuticas. 
 
Métodos: Linhas celulares de rim normal (HKC-8 e HK-2) e de CCRs (769-P, Caki-1, Caki-
2 e ACHN) foram utilizadas para avaliar o efeito do lactato na regulação das enzimas 
epigenéticas e consequentes alterações no crescimento celular, proliferação, migração e 
invasão. Foram também avaliados os efeitos in vitro do tratamento com nicotinamida [um 
inibidor da atividade das Sirtuinas (SIRTs)] e com alfa-ciano-4-hidroxicinamato [CHC, um 
inibidor dos transportadores de monocarboxilatos (MCTs)]. Posteriormente, através da 
análise imunohistoquímica numa série de tecidos tumorais de CCRs e de tecidos normais 
de rim foi avaliada a expressão do HIF-1, da SIRT1 e da SIRT6. 
 
Resultados: O lactato inibe as SIRTs (Classe III das histonas desacetilases) em linhas 
celulares de CCRs. Foi encontrada uma diminuição na expressão da SIRT1, SIRT3 e 
SIRT6 que induziu a hiperacetilação das histonas H3 e H4, assim como o aumento da 
acetilação das marcas de histona específicas H3K9 e H4K16. As células tratadas 
apresentaram um aumento no fenótipo glicolítico devido ao aumento de expressão do HIF-
1 e MCTs, juntamente com um aumento na migração, invasão e agressividade celular. 
Para além disso, o lactato induziu alterações semelhantes nas linhas celulares de rim 
normal, sendo o seu efeito associado a uma possível transformação tumoral. O tratamento 
com Nicotinamida levou aos mesmos efeitos observados para o lactato na expressão das 
SIRTs, promovendo a agressividade celular. Por outro lado, o CHC reverteu estes efeitos 
através do bloqueio do transporte do lactato. A análise imunohistoquímica revelou um 
aumento da expressão do HIF-1 e uma diminuição na expressão da SIRT1 e SIRT6 nos 
tecidos de CCRs em comparação com os tecidos renais normais. 
 
Conclusões: Este estudo revelou um novo papel do lactato na agressividade dos CCRs e 
na transformação maligna das células normais adjacentes através de um mecanismo 
mediado pelas SIRTs. Estes dados conduzem à descoberta de novas estratégias no 
tratamento de pacientes com CCRs. 
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ABSTRACT 
 
Background: Renal cell carcinoma (RCC) characteristically displays a glycolytic phenotype 
(Warburg effect) with increased lactate production. Lactate, which has an important role in 
tumor biology and microenvironment modulation, has recently been reported to modulate 
epigenetic mechanisms, leading to histone deacetylases inhibition. Thus, in-depth 
knowledge of lactate’s role in epigenome regulation of highly glycolytic tumors might entail 
the discovery of new therapeutic strategies. Herein, we investigated the interaction between 
metabolism and epigenetics in RCC. 
 
Methods: The lactate’s effect on epigenetic enzymes was evaluated in normal kidney 
(HKC-8 and HK-2) and RCC (769-P, Caki-1, Caki-2 and ACHN) cell lines, and alterations 
in cell growth, proliferation, migration, and invasion were assessed. In vitro effects of 
nicotinamide [Sirtuins (SIRTs) inhibitor] and alpha-cyano-4-hydroxycinnamate [CHC, a 
monocarboxylate transporters (MCTs) inhibitor] on cell phenotype were also assessed. 
Finally, HIF-1, SIRT1 and SIRT6 expression was evaluated by immunohistochemistry in 
a series of human RCC tumors and normal kidney tissues. 
  
Results: Lactate inhibited SIRTs (Class III histone deacetylases) in RCC cell lines. SIRT1, 
SIRT3 and SIRT6 expression was downregulated, inducing histone H3 and H4 
hyperacetylation, as well as increasing acetylation in specific histone marks H3K9 and 
H4K16. Cells exposed to lactate displayed a pronounced glycolytic phenotype through 
upregulation of HIF-1 and MCTs, disclosing increased cell migration, invasion and 
aggressiveness. Furthermore, lactate exposure induced similar alterations in normal kidney 
cell lines, which acquired some malignant features (pseudo-transformation). Nicotinamide 
treatment paralleled lactate effects, promoting cell aggressiveness. In contrast, CHC 
reversed these effects by blocking lactate transport. Primary RCC disclosed HIF-1 
upregulation whereas SIRT1 and SIRT6 were downregulated compared to normal tissues. 
 
Conclusions: In RCC, lactate enhances tumor cell aggressiveness and modulate normal 
cell phenotype, through downregulation of SIRTs, unveiling tumor metabolism as a 
promising therapeutic target in RCC. 
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RENAL CELL CARCINOMA 
Epidemiology and risk factors of renal cancer 
 Renal cancer (RC) is the 16th most incident cancer worldwide according to 
GLOBOCAN 2018 estimates, being responsible for approximately 2% of all cancer related 
deaths [1]. In 2018 were estimated 403,000 new cases, among which two thirds in men [1]. 
Moreover, RC have a highest incidence rates in developed regions, in which the top 10 of 
more incident cancers in Northern America, Australia/New Zealand and Europe (Figure 1). 
In Europe, Portugal reports the lowest incidence and mortality, below 6.3 per 100 000 and 
1.7 per 100 000, respectively [1]. 
 
 
Figure 1. Worldwide RC incidence. 2018 global incidence rates for both sexes estimated age-standardized 
(per 100 000). Adapted from [1]. 
 
 Advanced age is an important factor for development of many cancers, including 
RC. Despite RC can appear also in young patients, the incidence is markedly linked to age, 
being the highest incidence found between 60 and 70 years [2]. Gender is other factor that 
interferes in RC incidence and mortality, once these are 50% lower in women compared to 
men [3]. Men not only have a highest probability to have RC but also present larger tumors 
and in more advanced stages than women [4]. The gender disparities probably occurs due 
to differences in smoking habits, occupational risk factors and sex steroid hormones [5]. 
 Cigarette smoking, obesity and hypertension are the principal recognized risk factors 
for RC [6], nevertheless other medical conditions, like kidney stones, urinary tract infection 
and chronic kidney disease, have also been associated with increased risk [7]. Tabaco 
consumption have a strong dose-dependent effect in RC risk for both genders. Compared 
with never smokers, smoking increase risk in 50% for males and 20% for females [8]. 
Hypertension, as well as antihypertensive drugs are also associated with increased risk of 
RC [9]. Additionally, excess body weight can duplicate the risk of RC [10, 11]. 
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 Genetic factors can also lead to a two-fold increased risk in RC [12]. Approximately 
2-3% of all RC are associated with family history, and several distinct genetic alterations 
are described [13]. The most common familiar syndrome found in RC is Von Hippel Lindau 
(VHL) disease, caused by inactivating mutations of the VHL tumor suppressor gene, which 
contributes to increased risk of clear cell renal cell carcinoma (ccRCC), and other diseases 
like pheochromocytomas and hemangioblastomas [14]. 
 
Molecular subtypes  
 Renal Cell Carcinoma (RCC) is the most common RC type, representing 
approximately 80% of these [13]. RCC arises from nephron renal tubular epithelial cells 
[15]. This heterogeneous disease comprises more than 10 histopathological and molecular 
subtypes [16]. The ccRCC subtype encompasses approximately 75% of all RCC, followed 
by papillary RCC (pRCC) and chromophobe (chRCC), that make up approximately 10% 
and 5%, respectively [15]. 
 
Clear cell renal cell carcinoma 
 CcRCC can appear in sporadic or hereditary forms [17]. Hereditary syndromes only 
represent a small percentage of ccRCC cases, hence more than 80% of cases are sporadic 
ccRCC [13]. Majority of familiar ccRCC are associated with von Hippel Lindau disease, 
caused by mutations in VHL gene located in chromosome 3p (3p25-26) [18]. Furthermore, 
other hereditary forms, like mutations in BRCA1 associated protein 1 (BAP1) gene and in 
succinate dehydrogenase (SDHB, SDHC and SDHD) genes, have been associated with 
ccRCC [18]. 
 In approximately 90% of sporadic cases were identified loss of chromosome 3p, that 
is related with VHL gene mutation [19]. Biallelic inactivation of VHL gene is a driving event 
in ccRCC carcinogenesis, caused by point mutations, loss of 3p25 and indels, and/or by 
VHL promoter hypermethylation [20]. The VHL protein is part of ubiquitin ligase complex 
responsible to target hypoxia-inducible factors (HIF) 1 and 2 for degradation [21, 22]. 
Under normoxic conditions, HIFs suffer hydroxylation on conserved proline residues by 
prolyl hydroxylase (PHD) proteins. The HIF- hydroxylated proteins enable the VHL 
complex binding, which target these proteins for ubiquitination and proteasomal 
degradation [23]. In hypoxia, HIF- are not hydroxylated by PHD once these proteins are 
inactive [24]. As consequence, HIF- accumulates in the nucleus, resulting in transcription 
of HIF target genes that regulate several pathways such us glycolysis, cell proliferation and 
angiogenesis (Figure 2) [25]. In ccRCC, loss of VHL leads to a pseudo-hypoxic condition 
with abnormal accumulation of HIF proteins even with normal oxygen levels [26, 27]. 
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Figure 2. HIF regulation by oxygen-dependent degradation mechanism. Under normal oxygen levels 
(normoxic conditions), HIF- is hydroxylated by PHDs proteins. VHL complex, composed by pVHL, ELB and 
ELC, CUL2 and RBX1, binds to hydroxylated HIF- and marks it with ubiquitylation (grey circles) for proteasomal 
degradation. Without oxygen (hypoxic conditions), PHDs are inactive allowing HIF- accumulation in cytosol. 
After translocation to the nucleus, HIF- form heterodimers with HIF-1β and binds to HRE inducing gene 
transcription. Abbreviations: CUL2 – Cullin 2, ELB – Elongin B, ELC – Elongin C, HIF – Hypoxia-inducible factor, 
HRE – Hypoxia-response elements, PHD – Prolyl hydroxylases, pVHL – VHL protein, RBX1 – Ring-box 1. 
Adapted from [23]. 
 
 Additionally, along with VHL loss, mutations in other genes located in chromosome 
3p have also been reported for ccRCC [19]. For example, mutations on chromatin 
remodelling genes, like polybromo 1 (PBRM1), SET domain containing 2 (SETD2) and 
BAP1, and activation mutations in mammalian target of rapamycin (mTOR) pathway, are 
prevalent in ccRCC and have been associated with worse prognosis [19].  
 
Papillary renal cell carcinoma 
 The pRCC comprises a heterogeneous group of tumors with distinct histological and 
cytogenetical characteristics, and divergent disease progression and outcomes [13]. 
Similarly to ccRCC, pRCC usually occurs in sporadic forms, but hereditary syndromes play 
also a role in pRCC arising [28]. Papillary can be divided in two major subtypes, pRCC Type 
I and pRCC Type II [29].  
 Type I is less frequent and has better prognosis, when compared to Type II [30]. 
Besides, it is typically associated with MET proto-oncogene (MET) mutations, however, only 
13-23% of sporadic cases harbor these mutations [31]. Despite that, the majority of Type I 
papillary tumors show amplification of the MET locus or overexpression of this gene [32]. 
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On the other hand, hereditary papillary renal cancer (HPRC), the familiar form of pRCC 
Type I, is characterized by activating mutations in the tyrosine kinase domain of MET, which 
is located in chromosome 7p [33, 34]. MET encodes a cell surface receptor that binds to 
the hepatocyte growth factor (HGF), inducing the activation of several pathways responsible 
for cell proliferation, survival and morphogenesis [35]. Thus, sporadic form with MET 
mutations and hereditary syndromes of pRCC Type I share the same morphological 
phenotype [32]. Nevertheless, pRCC Type I tumorigenesis is not only associated with MET 
mutations, once gains in chromosomes 3q, 7, 12, 17, 20 are frequently found in genetic 
analysis [36]. 
 Contrary to Type I, MET mutations are not found in Type II pRCC, but in a few cases 
can be observed gene amplification [29]. Like Type I, pRCC Type II might occur in sporadic 
or familiar forms. Sporadic Type II tumors are frequently associated with cyclin dependent 
kinase inhibitor (CDKN) 2A inactivation, either by mutation or promoter hypermethylation. 
Additionally, mutations on chromatin remodeling genes (SETD2, BAP1 and PBRM1 genes) 
described for ccRCC were also found [29]. The familiar form arises from hereditary 
leiomyoma renal cell carcinoma (HLRCC). This hereditary syndrome is characterized by 
germline mutations in fumarate hydratase (FH) gene [37]. FH-deficient tumors display 
fumarate accumulation that inhibit the activity of PHD, resulting in a pseudo-hypoxic 
environment do to HIF- accumulation [38]. Thus, loss of FH expression is deeply 
connected to increased expression of hypoxia related genes associated with cell 
progression and glycolytic metabolism [29, 39].  
 
Diagnosis and current therapies  
 Nowadays, the majority of RCC cases are detected incidentally by abdominal 
ultrasound scanning or computed tomography imaging during routine evaluation, and only 
a small percentage of patients (approximately 30%) are diagnosed after presenting 
symptoms like flank pain, gross haematuria and palpable abdominal mass [13]. Besides, 
RCC are typically linked with paraneoplastic syndromes such as hypertension, anemia and 
cachexia [40]. In most part of the cases, RCC is diagnosed at initial stages, once 
incidentalomas are usually of small size and with good prognosis. Moreover, about 20% of 
patients already present metastases at the time of diagnosis. In early stages, 5-year survival 
rates are higher than 85%, but survival rate decreases to less than 20% when it comes to 
metastatic disease [41].  
 Despite the advances in targeted therapies, surgery remains the mainstay of RCC 
treatment. Early stages RCC can undergo partial or radical nephrectomy depending on the 
patients features [42]. In advanced stages, surgery is as well performed, but in these cases 
radical nephrectomy is carried along lymph node dissection, adrenalectomy, and/or venous 
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thrombectomy [43]. Additionally, in patients with isolated resectable metastases, 
metastectomy is recommended and can be performed during primary tumor resection [44]. 
Nevertheless, systemic therapy has traditionally been used in patients’ metastatic disease. 
Therapies based on immune system modulators, such as interferon-alfa and interleukin (IL) 
2, did not have a great impact in patient outcomes [45]. In the past decade, significant 
improves have been made, and new targeted therapies have arisen as an alternative to 
current therapies [46]. Antiangiogenic agents, like tyrosine kinase inhibitors targeting the 
vascular endothelial growth factor (VEGF) signaling pathway, are currently available due to 
strong vascularization present in RCC. Furthermore, mTOR inhibitors as well as immune 
checkpoint inhibitors have been also used with improvements in response rates [47]. 
Notwithstanding the progress in this field, RCC is still associated with high recurrence rates, 
and a substantial part of patients with localized disease develop metastasis during follow-
up [48, 49]. Thus, the identification of new tumor-associated markers that allowing the 
design of new therapeutic strategies in management of RCC patients are crucial. 
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TUMOR METABOLISM 
Warburg effect 
 In the last decades, remarkable progress in research have been made to deepen 
knowledge on mechanisms behind carcinogenesis and tumor biology. Several efforts led to 
expansion of classical cancer hallmarks, with recognition of new emerging hallmarks, such 
as reprogramming of energy metabolism (Figure 3) [50]. Nowadays, metabolic switch is a 
well substantiated mechanism essential to tumor initiation and progression, once it supports 
cell growth and division [50].  
 
 
Figure 3. Hallmarks of cancer. The cancer hallmarks comprise biological mechanisms adaptations that cancer 
cells suffer during development and contributes to complexity of neoplastic disease. Adapted from [50]. 
 
 In normal quiescent cells or differentiated tissues, under aerobic conditions, glucose 
is converted into pyruvate via glycolysis, and then transported from the cytosol to the 
mitochondria where is converted in acetyl-coenzyme A (acetyl-CoA). Thereafter, acetyl-
CoA enters in the tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OXPHOS) 
is performed. In this conditions, the cells show basal glycolysis rate and most part of 
adenosine triphosphate (ATP) is provided from OXPHOS [51]. On the other hand, in lack of 
oxygen, glycolysis is favored and pyruvate is metabolized to lactate instead of acetyl-CoA 
through anaerobic glycolysis [50]. Proliferative cells undergo a metabolic switch, due to 
bioenergetic and biosynthesis needs. These cells have an increase in glucose consumption 
as well as high glycolytic rates, lactate production, and biosynthesis of lipids and other 
macromolecules (Figure 4) [52].  
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Figure 4. Alternative mechanisms in normal and tumor cells for generating energy using glucose as 
fuel. Normal differentiated cells, in presence of oxygen, perform oxidative phosphorylation though pyruvate 
oxidation provided by glycolysis. In the absence of oxygen, these cells replace oxidative phosphorylation for 
anaerobic glycolysis synthesizing lactate from glucose. Similarly, normal proliferative cells and cancer cells 
produce lactate from pyruvate in an oxygen-independent way by a process denominated aerobic glycolysis 
(Warburg effect). Abbreviation: Acetyl-CoA – Acetyl-coenzyme A, TCA – Tricarboxylic acid cycle. Adapted from 
[52]. 
 
 Tumor cells share the metabolic signature of proliferating cells in order to fuel cell 
growth and division [53]. In fact, the highly glycolytic cancer cell metabolism is sustained 
even in the presence of oxygen, and is designated by aerobic glycolysis or Warburg effect 
[53, 54]. As a result, in tumor cells, most of the incoming glucose is converted into lactate 
(approximately 85%), and just a small percentage of pyruvate produced by glycolysis is 
metabolized in the mitochondria through OXPHOS (around 5%) [52]. Compared to 
mitochondrial OXPHOS, glycolysis is bio-energetically less efficient, since glucose 
metabolism generate less ATP than OXPHOS [55]. Although, increased glycolysis allows 
rapid ATP synthesis in the cytoplasm [56, 57]. Furthermore, glycolysis is sustained by 
preservation of nicotinamide adenine dinucleotide (NAD)+/NADH ratio, once NAD+ 
consumed in this reaction is regenerated during pyruvate conversion to lactate [51, 58]. In 
fact, metabolic reprogramming confers several advantages to tumor cells [59]. First, 
glycolysis supports biosynthesis of lipids, amino acids and also nucleotides by providing 
intermediates of the glycolytic pathway for anabolic reactions. Cancer energy metabolism 
allows cells survive and proliferate under fluctuating oxygen availability conditions. 
Additionally, Warburg effect protect cells from oxidative stress by promoting a homeostasis 
of reactive oxygen species (ROS) production due to antioxidant glutathione production. 
Moreover, increase glycolysis leads to greater lactate production which contributes to 
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microenvironment acidification contributing to acquisition of a more invasive phenotype with 
increased migration, invasion, metastization, as well as, immunosuppression and therapy 
resistance [56, 57, 59]. 
 Interestingly, in tumor heterogeneity was been found a symbiotic relationship 
between two cancer cells populations. Taking in account the blood vessels distribution, the 
tumor cells are exposed to different O2 levels. The hypoxic cancer cells are more distant 
from the blood vessel and are poorly oxygenated. These cells have high HIF-1α expression, 
which induces glycolytic proteins expression, increasing glucose uptake and lactate 
production, as well as, lactate efflux for tumor microenvironment. On the other hand, well 
oxygenated tumor cells are able to perform lactate uptake and preferentially use them as 
main energy source, by employing as principal substrate for mitochondrial OXPHOS (Figure 
5) [60, 61]. Knowing that both tumor metabolic reprograming and intra-tumoral symbiosis 
have an important role in tumor growth and therapy resistance, new anti-cancer therapies 
targeting cancer bioenergetics have been developed. 
 
 
Figure 5. Metabolic reprograming in intrartumoral symbiosis. Glycolytic cells away from the blood vessels 
have low oxygen levels available. These cells consume glucose to performed anaerobic glycolysis generating 
lactate to the tumor microenvironment. On the other hand, tumor cells well oxygenated due to the proximity with 
blood vessel do the lactate uptake and conversion to pyruvate in order to perform oxidative phosphorylation 
OXPHOS. Abbreviations: GLUT – Glucose transporter, HIF – Hypoxia-inducible factor, LDH – Lactate 
dehydrogenase, MCT – Monocarboxylate transporter, TCA – Tricarboxylic acid cycle. Adapted from [61]. 
 
Metabolic issues in renal cell carcinoma 
 As described in previous section, RCC is characterized by mutations in genes 
related with cell metabolism, namely FH and SDH genes. FH and SDH-deficient RCC have 
accumulation of fumarate or succinate, respectively, which inhibits the PHDs. Without PHDs 
action, HIF is stabilized and accumulates in the cytosol. In addition to FH and SDH 
mutations, loss of function of VHL gene is also found in a large percentage of RCC cases. 
As we see before, VHL is responsible for HIF degradation, and when this protein is not 
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present, HIF is stabilized, leading to HIF pathway activation (Figure 6) [62, 63]. Furthermore, 
activation of mTOR and MET pathways is another characteristic of RCC carcinogenesis, 
that increases to HIF translation [62]. This RCC features increased transcription of HIF-1α 
target genes related to glucose metabolism, cell proliferation and angiogenesis, which 
contribute not only for a high glycolytic phenotype, but also to cancer progression [64, 65]. 
 
 
Figure 6. Warburg effect in RCC. Succinate and fumarate accumulation, as well as VHL inactivation leads to 
increased glycolytic metabolism by HIF pathway activation. Abbreviations: FH – Fumarate hydratase, GLUT – 
Glucose transporter, HIF – Hypoxia-inducible factor, HRE – Hypoxia-response elements, LDH – Lactate 
dehydrogenase, PDGF – Platelet derived growth factor, PHD – Prolyl hydroxylases, pVHL – VHL protein, SDH 
– Succinate dehydrogenase, TGF – Transforming growth factor, VEGF – Vascular endothelial growth factor. 
Lameirinhas A. unpublished. 
  
 HIF-1 constitutive upregulation in RCC was associated to increase transcription of 
genes encoding several glucose transporters (GLUT) 1 and 3, and glycolytic enzymes, like 
hexokinases (HK) 2, glucose phosphatase isomerase (GPI) and phosphoglycerate kinase  
(PGK) 1 [66]. The upregulation of these genes indicates that RCC cells use preferentially 
the glycolytic pathway, even in the presence of oxygen. Moreover, hypoxia response 
elements also increase expression of lactate dehydrogenase (LDH) A and monocarboxylate 
transporter (MCT) 4, suggesting that pyruvate produced via glycolysis is metabolized into 
lactate [64, 67]. Additionally, the high pyruvate dehydrogenase kinase (PDK) 1 expression 
was found in RCC tissues. This enzyme inhibits the pyruvate dehydrogenase (PDH) activity 
responsible for the conversion of pyruvate to acetyl-CoA, leading to TCA cycle deprivation 
[68]. On the other hand, downregulation of proteins from respiratory complexes contributes 
to mitochondrial activity depletion [66, 68]. Thus, RCC display increased glycolysis and 
lactate production along with reduced OXPHOS, characteristic of Warburg effect (Figure 7). 
 Besides glycolysis, other metabolic enzymes related to fatty acids metabolism, 
glutaminolysis and pentose phosphate pathway (PPP) are also deregulated in RCC (Figure 
7) [67, 69, 70]. RCC disclose increased activity of the PPP supported by overexpression in 
glucose-6-phoshate dehydrogenase (G6PD) [71, 72]. The PPP generate high nicotinamide 
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adenine dinucleotide phosphate (NADPH) levels which is critical in defense against 
oxidative stress, apoptosis and radiation, and provides ribose need for nucleotide 
biosynthesis [71]. Additionally, enzymes of fatty acids synthesis pathway, namely acetyl-
CoA carboxylase (ACC) and fatty acid synthase (FAS) were found increased in RCC and 
associated with tumor aggressiveness and poor prognosis [19, 73]. Nevertheless, 
upregulation of glutamine metabolism in RCC was associated to MYC proto-oncogene 
(MYC) overexpression, which induce glutamine transporter and glutaminase (GLS) 
upregulation [74]. Increase glutaminolysis is accompanied by elevated levels of glutamate 
and α-ketoglutarate, as well as, accumulation of lipids in RCC tumors [74]. 
 
 
Figure 7. Metabolic reprogramming in RCC. Renal cell carcinomas are characterized by a high glycolytic 
phenotype with increased lactate production, where glucose is the major energy source. Pentose phosphate 
pathway, fatty acid synthesis and glutaminolysis are also increased to sustain nucleotides, amino acids and 
lipids biosynthesis. In contrast, TCA cycle activity is decreased in these tumors. In the scheme proteins that 
were found upregulated in renal cell carcinoma are labeled red, while downregulated proteins are labeled blue. 
Abbreviations: ACC – Acetyl-coenzyme A carboxylase, Acetyl-CoA – Acetyl-coenzyme A, ALDO – Fructose-
bisphosphate aldolase, ENO – Enolase, FAS – Fatty acid synthase, FH – Fumarate hydratase, G6PD – 
Glucose-6-phoshate dehydrogenase, GAPDH – Glyceraldehyde-3-phosphate dehydrogenase, GLS – 
Glutaminase, GLUT – Glucose transporter, GPI – Glucose phosphatase isomerase, HK – Hexokinase, IDH – 
Isocitrate dehydrogenase, LDH – Lactate dehydrogenase, MCT – Monocarboxylate transporter, OAA – 
Oxaloacetate, PDH – Pyruvate dehydrogenase, PDK – Pyruvate dehydrogenase kinase, PFK – 6-
phosphofructokinase, PGK – Phosphoglycerate kinase, PKM - Pyruvate kinase M, SDH – Succinate 
dehydrogenase, SLC1A5 – Solute carrier family 1 member 5, TCA – Tricarboxylic acid cycle, α-KG – Alpha-
ketoglutarate. Adapted from [69]. 
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Role of lactate in tumor microenvironment  
 Solid tumors, like RCC, have a constitutive increase in the glycolytic phenotype as 
common feature, followed by high lactate production [56]. Owing to lactate efflux with co-
transport H+ through MCTs, the cancer cells maintain the intracellular pH at physiological 
levels. At the same time, this leads to tumor microenvironment acidification [75], that is 
associated with increased tumor aggressive behavior by promotion of migration, invasion, 
angiogenesis and immune scape [76]. Furthermore, lactate has an important role in the 
tumor microenvironment by supporting tumor growth and proliferation. Accordingly, lactate 
act as a metabolic fuel in tumor symbiosis described before, as well as signaling molecule 
[61, 77]. Lactate contributes to several features in cancer progression, like increased 
migration, invasion, sustained angiogenesis, immune escape and therapy resistance [78-
80]. Moreover, high lactate levels have been associated with poor prognosis, high 
metastasis risk and high tumor recurrence in several solid tumors [81].  
 Taking in account lactate influence in tumor microenvironment, several studies 
recognized its role as a migration and angiogenic promoter. HIF-1α stabilization by lactate 
was recently described, and is responsible for increasing the production of VEGF and this 
kinase insert domain receptor (VEGFR2) by tumor and endothelial cells, respectively [82]. 
Moreover, Vegran, F. et al. showed that lactate also induces IL-8 production by endothelial 
cells in a HIF-1α-independent way [83]. Another example is the effect of lactate in 
angiogenesis modulation by stabilization of N-Myc downstream-regulated (NDRG3) protein 
expression in cancer cells, which promotes up-regulation of VEGF, IL-8 and platelet and 
endothelial cell adhesion molecule 1 (CD31) levels, under long hypoxia periods [84].  
 Regarding immune surveillance evasion, lactate decrease cytotoxic activity of T cells 
and natural killer cells, as well as, dendritic cells cytokine release and differentiation [80]. 
Additionally, lactate-induced HIF-1 stabilization stimulates polarization of tumor-
associated macrophages, contributing to immunosuppression [85]. Lastly, a study in human 
squamous cell carcinomas in nude mice demonstrated that tissue lactate content predicts 
the response to fractionated irradiation [86]. Another study suggests that lactate antioxidant 
properties is responsible for this positive correlation found between tumor lactate content 
and radioresistance in solid human tumors [87]. 
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EPIGENETIC MECHANISMS  
 Epigenetics are described as heritable and reversible changes in gene expression 
patterns that result from alterations in chromatin and not in DNA sequence [88]. Epigenetic 
marks are crucial to maintain genomic stability, chromosome imprinting and cell 
differentiation in normal cells development [89]. However, cells epigenetic landscape 
plasticity can be molded by genetic, environmental or metabolic stimuli that allows cell 
adaptation and contributes to malignant transformation [90]. Epigenetic deregulation is a 
cancer hallmark, it is present in early stage of cancer development and may precede genetic 
mutations events. Cancer epigenome is characterized by genomic instability and global 
gene expression deregulation with activation of proto-oncogenes and silencing of tumor 
suppressors genes due to changes in DNA methylation, histone modification patterns and 
expression profiles of chromatin remodeling enzymes (Figure 8) [91, 92]. 
 
 
Figure 8. Epigenetic mechanisms in gene expression regulation. Chromatin remodeling complexes, histone 
variants, histone post-translational modifications and DNA methylation regulate gene transcription and DNA 
stability through alterations in chromatin structure. Adapted from [93]. 
 
DNA methylation 
 DNA methylation is the most well study epigenetic mechanism. In cancer, DNA 
methylation occurs mostly in cytosines of gene promoter cytosine-phosphate-guanine 
(CpG) islands, and results in transcription repression [94]. The DNA methyltransferases 
(DNMT1, DNMT3a and DNMT3b) enzymes are the responsible for catalyze the transfer of 
a methyl group from S-adenosyl-L-methionine (SAM) to 5’ carbon of cytosine ring, resulting 
in 5-methyl-cytosine (5mC) (Figure 9) [95]. These enzymes have different function on the 
cell. DMNT1 acts in DNA methylation patterns maintenance during replication by completing 
the hemi-methylated sites [96]. In contrast, DNMT3a and DNMT3b are responsible for de 
novo methylation establishment by adding methyl groups in unmethylated DNA duplex [97]. 
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Nevertheless, DNA methylation process can be reverted by ten-eleven translocation (TET) 
proteins that catalyze the oxidation of 5mC to 5hmC (5-hydroxymethyl-cytosine) in α-
ketoglutarate-dependent oxidation manner (Figure 9) [98]. 
 In normal cells, DNA methylation is associated with repetitive genomic regions, 
whereas gene promoters’ are generally unmethylated [99]. On the other hand, tumor cells 
are characterized by alterations in DNA methylation profile. In general, cancers display 
global hypomethylation that results in genome instability with proto-oncogenes activation, 
loss of imprinting and high mutation rates. Furthermore, aberrant gene promoter 
hypermethylation in cancer is associated with transcription silencing of tumor suppressor 
genes involved in several cell functions regulation, such as DNA repair, cell signaling and 
cell-cycle regulation [99, 100]  
 
 
Figure 9. DNA methylation regulation. DMNTs catalyze cytosine methylation to 5mC using SAM as a methyl 
donor, which is converted to SAH. TETs revert DNA methylation by convert 5mC into 5hmC by a hydroxylation 
α-ketoglutarate-dependent reaction. DNA methylation regulates gene transcription, once gene promoter 
hypermethylation blocks transcription. Abbreviations: 5hmC – 5-hydroxymethyl-cytosine, 5mC – 5-methyl-
cytosine, CpG – Cytosine-phosphate-guanine, DMNT – DNA methyltransferase, SAH – S-
adenosylhomocysteine, SAM – S-adenosyl-L-methionine, TET – Ten-eleven translocation, -KG – Alpha-
ketoglutarate. Adapted from [93]. 
 
Histone post-translational modifications 
 Covalent modifications on histone tails regulate the chromatin structure controlling 
DNA transcription, replication and repair [101]. The most important post-translational 
modifications (PTMs) are methylation and acetylation of particular amino acids motifs of 
histones’ core. These are controlled by histone methyltransferases (HMTs) or histone 
acetyltransferases (HATs), that establish the marks, and by histone lysine demethylases 
(KDMs) or histone deacetylases (HDACs), that removed them [102]. 
 Regarding histone methylation, HMTs catalyze the methylation reaction in lysine or 
arginine residues of histone tails using SAM as a methyl donor. To revert these condition, 
KDMs by oxidation remove the methyl group from a methylated lysine in a flavin adenine 
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dinucleotide (FAD) or α-ketoglutarate (α-KG) dependent manner (Figure 10) [103]. Histone 
methylation and consequent alteration on transcriptional status is dependent on the 
methylation degree and the residue modified. Trimethylation of H3K4 is found in 
transcriptionally active promoter genes, however H3K9me and H3K27me3 marks are 
associated with transcriptional repression [104]. These enzymes have been found 
deregulated in several tumors. Indeed, overexpression of HMTs SET and MYND domain 
containing 3 (SMYD3) and enhancer of zeste 2 polycomb repressive complex 2 subunit 
(EZH2) was observed in several solid tumors and are associated with tumor malignancy 
[105, 106]. Additionally, H4K20me3 histone mark is usually found in human cancers [107].  
 
 
Figure 10. Histone methylation mechanisms. Histone methylation patterns are stablished by HMTs. In the 
reaction SAM is used as methyl donor and converted into SAH. Inversely, histone demethylases KDMs remove 
the methyl group of histone tails using FAD+ or -KG as cofactor. Abbreviations: FAD – Flavin adenine 
dinucleotide, HMT – Histone methyltransferase, KDM – Histone lysine demethylase, SAH – S-
adenosylhomocysteine, SAM – S-adenosylmethionine, -KG – Alpha-ketoglutarate. Adapted from [93]. 
  
 Acetylation is another well studied PTM. This histone mark is established by HATs 
that add an acetyl group at lysine residues of histone N-terminal tails. This reaction is 
dependent of acetyl-CoA that acts as acetyl donor [108]. The addition of an acetyl group 
neutralizes the positive charges of histones decreasing DNA compaction, allowing the 
protein binding and transcription activation [109]. Contrarily, acetylation loss leads to DNA 
condensation by restoring the positive charges of lysine, with consequent transcription 
abrogation [109]. Thereby, HDACs are responsible to remove the acetyl groups of histone 
tails and are divided in four classes [110]. The Class I, II and IV share a catalytic mechanism 
in which zinc is used to catalyze hydrolysis of the lysine-amino bond [111]. Conversely, 
HDAC Class III, Sirtuins (SIRTs), rely on NAD+ for deacetylation activity (Figure 11) [112]. 
HATs and HDACs enzymes’ deregulation has been implicated in tumorigenesis, tumor 
invasion and metastasis [113]. Indeed, loss of histone H4 Lys16 acetylation is defined as a 
common step in cancer development [107]. Moreover, hypoacetylation in H3K9 histone 
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mark is associated with a high proliferative prolife and with a higher recurrence rates in 
ependymal tumors [114].  
 
 
Figure 11. Histone acetylation mechanisms. HATs have as function the imprinting acetylation marks in 
histone. During the process, HATs transfer the acetyl group of acetyl-CoA to histone tails. Histone acetylation 
marks can be removed by HDACs using as co-factor NAD+ or Zn2+. Abbreviations: Acetyl-CoA – Acetyl-
coenzyme A, CoA-SH – Coenzyme A, HAT – Histone acetyltransferase, HDAC – Histone deacetylase, NAD – 
Nicotinamide adenine dinucleotide. Adapted from [93]. 
 
Epigenetic alterations in renal cell carcinoma 
 Epigenetic mechanisms allows cells' adaptation to environmental changes, fueling 
cancer cells malignant phenotype by supporting cell proliferation and metabolic 
reprogramming [115]. In RCC, alterations in DNA methylation profile and deregulation of 
genes involved in histone modifications and chromatin remodeling are frequently found 
[116]. 
  RCC commonly present considerable high methylation levels of CpG islands 
associated with aggressive behavior and glycolytic phenotype, as well as poor overall 
survival [19, 29, 117]. In RCC, epigenetic silencing by gene promoter hypermethylation 
often downregulate genes related with Wnt/β-catenin and transforming growth factor (TGF) 
β pathway, pro-apoptotic genes, cell cycler regulator’ genes and genes responsible for cell 
adhesion [118], thus contributing to cancer proliferation and metastization and are 
frequently associated with poor prognosis [119].  
 Regarding chromatin remodeling enzymes, RCC frequently harbor BAP1 and 
PBRM1 inactivating mutations [120]. BAP1-deficient RCC tumors are associated with poor 
prognosis [121], whereas loss of PBRM1 expression increase tumor aggressive behavior 
[122]. Moreover, inactivating mutations in SETD2, KDM5C and KMD6A were also found in 
renal carcinomas [123]. As a result of HTMs and KDMs deregulation, RCC display a 
remarkable histone methylation profile. For example, lower global H3K4 methylation levels 
are found in RCC associated with poor prognosis and higher recurrence rates [124, 125]. 
H3K9 and H4K20 global methylation is also downregulated in RCC and correlates with 
tumor aggressiveness [125, 126]. Furthermore, lower H3K27 methylation levels were found 
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in RCC associated with pathological stage and grade, as well as lymph node and distant 
metastasis [127]. 
 In general, HDACs Class I and II seem to act as oncogenes. Indeed, association 
between HDAC1 and HDAC2 overexpression and high proliferation index Ki-67 was found 
[128]. Additionally, high HDAC3 expression levels were found in RCC tumor [129], however, 
Fritzsche, F. R., et al. described an inverse correlation between pathological stage and 
HDAC3 levels [128]. Moreover, in in vitro approach HDAC1 and HDAC6 overexpression 
was implicated with in cell invasion, migration and motility modulation in ccRCC cells, by 
increasing matrix metalloproteinase expression and decreasing acetylated α-tubulin 
expression [130]. Furthermore, by The Cancer Genome Atlas (TCGA) dataset analysis, 
high HDAC1 mRNA levels was found associated with ccRCC worse overall survival [130]. 
In a RCC cohort, HDAC6 expression was correlated with histologic grade and poor overall 
survival. Furthermore, high HDAC6 expression levels were independent poor prognostic 
factor in RCC [131]. In contrast, although HDAC9 was found to be downregulated in ccRCC 
samples comparing with normal adjacent tissues, high HDAC9 expression associated with 
poor prognosis [132]. Remarkably, global histone acetylation alterations were found 
downregulated in RCC and were connected with patients’ prognosis [133]. Decreased H3 
and H4 global acetylation associated with high tumor grade and advanced stages. H3ac 
lower levels also associated with distant metastasis and tumor progression [133, 134]. In 
addition, H3 acetylation restoring inhibited cell proliferation, induced apoptosis and cell 
cycle arrest in ccRCC cell lines [134]. On the other hand, Mosashvilli, D., et al. described 
H3K18ac levels as independent predictor of cancer progression after surgery for RCC 
localized disease [133]. 
 Regarding HDACs Class III, a recent study found a downregulation of SIRT1, SIRT3 
and SIRT6 in RCC samples compared with normal kidney tissues, suggesting their role as 
tumor suppressor genes. Further, in the same study, SIRT3 prove to be a potential 
prognostic marker for ccRCC once higher expression correlates with better patients’ 
outcome [135]. SIRTs modulate several cellular processes in addition to chromatin structure 
regulation, such as cellular metabolism and genomic stability maintenance [136]. Moreover, 
SIRT1, SIRT3 and SIRT6 downregulation in tumors associated with HIF-1-mediated 
glycolytic metabolism activation, contributing to tumor growth and glucose homeostasis 
[137-139]. 
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INTERPLAY BETWEEN METABOLISM AND EPIGENETIC MECHANISMS 
 Cancer cells display several genetic and epigenetic alterations that allow metabolic 
adaptation and sustains cell proliferation and survival [140]. The cancer metabolic switch 
leads to metabolites accumulation that influence the epigenetic mechanisms and 
consequent gene expression, once epigenetic enzymes involved in DNA and histone 
modifications require intermediates of cellular metabolic pathways as cofactors or subtracts 
to take care its functions [141]. For instance, acetyl-CoA, α-KG, SAM and NAD+ are some 
examples of the metabolites involved in epigenetic processes (Figure 12) [142]. 
Furthermore, metabolic pathways disruption can also lead to metabolites’ accumulation that 
inhibit epigenetic enzymes action, like coenzyme A (CoA-SH), S-adenosylhomocysteine 
(SAH), β-hydroxybutyrate (β-OHB), 2-hydroxyglutarate (2-HG), fumarate, succinate and 
lactate (Figure 12) [143]. 
 
 
Figure 12. Metabolic reprogramming in epigenetic enzymes modulation. Epigenetic mechanisms can be 
modulated by the available metabolites in the cell, contributing to aberrant gene expression. DNA and histone 
methylation can be decreased by inhibition of DNMTs and HMTs due to low SAM ratio available. On the other 
hand, fumarate, succinate and 2-HG, metabolites with a similarly structure to -KG, have a role in KDMs and 
TETs inhibition. Regarding histone acetylation, HATs activity is dependent of high acetyl-CoA/CoA-SH ratio. In 
contrast, HDACs activity can be inhibited by butyrate, β-hydroxybutyrate, pyruvate and lactate, whereas SIRTs 
activity is regulated by NAD+/NADH ratio. Abbreviations: 1-MNA – 1-methylnicotinamide chloride, 2-HG – 2-
hydroxyglutarate, Acetyl-CoA – Acetyl-coenzyme A, ATP – Adenosine triphosphate, CoA-SH – Coenzyme A, 
DNMT – DNA methyltransferase, HAT – Histone acetyltransferase, HDAC – Histone deacetylase, HMT – 
Histone methyltransferase, KDM – Histone lysine demethylase, NAD – Nicotinamide adenine dinucleotide, 
NNMT – Nicotinamide N-Methyltransferase, SAH – S-adenosylhomocysteine, SAM – S-adenosyl-L-methionine, 
SIRT – Sirtuin, TCA – Tricarboxylic acid cycle, TET – Ten-eleven translocation, -KG – Alpha-ketoglutarate, β-
OHB – Beta-hydroxybutyrate. Adapted from [93]. 
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Metabolic reprogramming of epigenetic landscape in renal cell carcinoma 
Renal cell carcinoma metabolism in histone acetylation modulation 
 RCC display a high glycolytic metabolism with increased pyruvate conversion into 
lactate [63]. Several studies reported that these two metabolites are HDACs inhibitors. 
Accordingly, increased tumor cell apoptosis was related with HDACs inhibition by pyruvate, 
suggesting a negative role in tumor formation for pyruvate [144]. On the other hand, in 
cancer cells most of pyruvate is directly converted into lactate to keep the NAD+/NADH ratio 
sustaining glycolysis needs. In its turn, the lactate inhibitory activity on HDACs Class I and 
II was reported for colon and cervical cancers. Lactate promotes histone acetylation and 
gene expression through HDAC-inhibition mechanism contributing to DNA repair and to 
anticancer therapy resistance [145, 146]. Furthermore, Martinez-Outschoorn et al. found 
increased histone acetylation levels after exposing breast cancer cells to lactate and also a 
consequent increased expression on stemness related genes, as well as an association 
between lactate induced genes and breast patients’ outcome. However, in this study 
lactate-associated acetylation was justified not by HDACs inhibition but through HATs 
activation by acetyl-CoA pool increase [147]. Additionally, other metabolites, such as 
butyrate and β-OHB, are also well known HDACs inhibitors [148, 149]. Interestingly, 
butyrate plays a dual role in cells’ epigenetic regulation. In cancer cells, Warburg effect 
leads to increased butyrate levels once this is not converted in acetyl-CoA. In these 
conditions butyrate accumulation inhibits HDACs Class I, II and IV activity and cell 
proliferation by transcription of pro-apoptotic genes [150]. Instead, when cells use butyrate 
as a fuel through acetyl-CoA production, proliferation is stimulated and cancer growth is 
facilitated [150]. Curiously, β-OHB seem to have a similar effect to butyrate. In absence of 
glycolytic metabolism, β-OHB is used as an oxidative energy source instead of epigenetic 
regulator, and induces tumor growth [151]. Although, in presence of glycolytic metabolism 
β-OHB is not converted into acetyl-CoA and its accumulates, leading to HDACs Class I and 
II inhibition [147]. Additionally, an in vivo study demonstrated a specific inhibition of HDACs 
Class I by β-OHB with consequent increase in global histone acetylation, which was 
correlated with oxidative stress resistance induction transcription and protection against 
oxidative stress [152]. In parallel, cancer glycolysis decreases NAD+/NADH ratio, essential 
for SIRTs activity, once these enzymes depend of NAD+ as a cofactor. Thus, SIRTs 
inhibition seems to contribute to hyperacetylation and aberrant gene transcription, leading 
to cancer progression [140]. Nevertheless, additional studies are still needed to better 
understand the interactions between metabolic status and SIRTs activity in cancer. 
 In RCC, glycolytic metabolism induced by HIF-1 pathway activation leads to TCA 
cycle suppression by blocking pyruvate conversion into acetyl-CoA [153]. In this situation, 
tumor cells use other sources to obtain acetyl-CoA essential for lipid synthesis, as well as 
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for HATs function [154]. Cancer cells can reprogram its metabolism to produce citrate 
mitochondrial, which is transported to cytosol and converted in acetyl-CoA through ATP-
citrate lyase [141]. In these conditions, acetyl-CoA has a role in histone acetylation in 
glucose and growth factor stimulation response [155, 156]. Cytosolic acetate is another 
acetyl-CoA source cytosolic acetate [141]. Under glucose restriction or hypoxic stress, 
acetate is used as an immediate metabolic precursor in fatty acid synthesis and also 
induces expression of genes involved in de novo lipid synthesis and cancer cell survival by 
promoting histone acetylation in specific promoter regions [157]. Additionally, acetyl-CoA 
generated from glutamine showed to be involved in histone acetylation inducing the 
expression of genes involved in lipid metabolism [158]. 
 Thus, in general, high glycolytic tumors like RCC seems to have global histone 
hyperacetylation and consequent aberrant gene transcription, due to increased HATs 
activity induced by acetyl-CoA, and also HDACs inhibition by several metabolites, that 
contribute to cancer progression and aggressiveness [140]. 
 
Renal cell carcinoma metabolism in DNA and histone methylation modulation 
 Fumarate and succinate accumulation are typically found in FH and SDH-deficient 
RCC. Both metabolites have been related to -KG-dependent histone inhibition and DNA 
demethylases, namely TETs and KDMs [159, 160]. In tumors with SDH mutations, 
succinate accumulation associated with DNA hypermethylation phenotype [161]. Inhibition 
of histone and DNA demethylases were associated with increased tumor malignancy and 
invasion potential by epigenetic silencing of genes involved in cell differentiation and 
epithelial mesenchymal transition (EMT) [161, 162]. Moreover, fumarate proved to have a 
similar role in tumor aggressiveness. Sciacovelli et al. demonstrate that intracellular 
fumarate accumulation drives changes in EMT genes, like zinc finger E-box binding 
homeobox (ZEB), snail family transcriptional repressor 1 (SNAI1) and vimentin (VIM), 
through inhibition of TETs epigenetic enzymes and consequent antimetastatic microRNA 
cluster downregulation in murine renal carcinoma cells [163]. 
 More recently, L enantiomer of 2- hydroxyglutarate (L-2HG) was found to be 
accumulated in RCC [164]. This metabolite is produced from -KG by LDHA under hypoxic 
conditions [165, 166] and was demonstrated to be a stronger inhibitor of TETs and KDMs 
enzymes [167, 168]. In RCC, increased L-2HG levels are mediated by L-2HG 
dehydrogenase (L2HGDH) reduced expression due to copy number loss [164]. Additionally, 
Shim et al. reported an inverse association between high L-2HG levels and reduced DNA 
5hmC levels due to TET activity inhibition [164]. On the other hand, L2HGDH restoring in 
RCC cells was associated with L-2HG decrease and consequent DNA and histone 
demethylation by re-activation of TETs and KDMs activity. Additionally, in in vitro assays 
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demonstrated that L2HGDH re-expression attenuates malignant phenotype by inhibiting L-
2HG oncogenic role in RCC [164]. 
 Hence, owing to mutations in FH, SDH and L2HGDH genes, RCC harbor aberrant 
accumulation of oncometabolites, which stimulates tumor growth and aggressiveness by 
TET and KMDs-inhibition [169, 170].   
  
 
 
 
 
 
 
 
 
AIMS
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 RCC cells are highly dependent of glycolytic metabolism, which lead to a high lactate 
production rate. Moreover, lactate has been implicated in tumor progression and therapy 
resistance. Once this metabolite accumulates in tumor microenvironment, the investigation 
of lactate’s role in epigenome regulation in high glycolytic tumors like RCC might be relevant 
not only to understand tumor biology but also to identify new therapeutic targets. 
 Thus, this study intends to explore the lactate’s effect in epigenetic machinery 
modulation, and respective impact in tumor aggressiveness and progression. Furthermore, 
its possible effect in neoplastic transformation of normal adjacent cells was also 
investigated.  
 
Accordingly, the specific aims for the project are: 
1. Evaluate lactate’s effect in epigenetic enzymes and consequent alterations on cell 
aggressiveness of kidney tumor cells. 
RCC lines (769-P, Caki-1, Caki-2 and ACHN) were exposed to lactate and 
consequent effect in epigenetic enzymes were assessed. Then, consequent 
alterations on cell growth, proliferation, migration, invasion and aggressiveness 
were analyzed. 
 
2. Assess the effect of lactate available in tumor microenvironment in normal kidney 
cells. 
The normal kidney cell lines (HKC-8 and HK-2) were exposed to lactate and 
conditioned medium (CM) from the tumor cells in order to evaluate its’ effect in 
epigenetic enzymes and phenotypic alterations. 
 
3. Explore the effect of specific MCTs and epigenetic enzymes inhibitors. 
The in vitro effects of nicotinamide (NAM) and CHC (alpha-cyano-4-
hydroxycinnamate) in kidney cell lines were assessed. 
 
4. Confirm the in vitro results in a series of human RCC tumors and normal kidney 
tissues.  
HIF-1, SIRT1 and SIRT6 expression was evaluated by immunohistochemistry 
(IHC) in a series of human RCC tumors and normal kidney tissues, and correlation 
analysis was performed between HIF-1 and SIRTs. 
 
  
  
 
  
 
 
 
 
 
 
 
MATERIAL AND 
METHODS 
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CELL LINES CULTURE 
 Epithelial human kidney cell lines (HKC-8, HK-2, 769-P, Caki-1, Caki-2 and ACHN) 
obtained from American Type Culture Collection (ATCC) were used (Table 1). In order to 
normalize the glucose quantity available, all cell lines were maintained in RPMI-1640 
Medium (Biochrom, MERK, Germany) supplemented with 10% fetal bovine serum (FBS, 
Biochrom, MERK, Germany) and 1% penicillin/streptomycin (GBICO, Invitrogen, USA) at 
37ºC and 5% CO2 in a humidifying chamber. Mycoplasma test was performed using 
TaKaRa PCR Mycoplasma Detection Set (Clontech Laboratories, EUA), before all 
experiments. 
 
Table 1. Clinical pathologic characterization of epithelial human kidney cell lines 
Kidney cell lines 
HKC-8 Human renal proximal tubule epithelial cells 
HK-2 Human renal proximal tubule epithelial cells 
769-P Primary clear cell renal cell carcinoma 
Caki-1 
Metastatic clear cell renal cell carcinoma 
(metastatic site: skin) 
Caki-2 Primary papillary renal cell carcinoma 
ACHN 
Metastatic papillary renal cell carcinoma 
(metastatic site: pleural effusion) 
  
 
TISSUE SAMPLES 
 A series of 80 RCC tissue samples comprising ccRCC and pRCC subtypes (40 
cases of each subtype), collected from patients submitted to radical or partial nephrectomy 
at the Portuguese Oncology Institute of Porto, Portugal between 2003 and 2007, were 
included in this study. Additionally, a set of 30 morphologically normal kidney (cortical) 
samples from nephrectomy specimens obtained from patients with low stage upper urinary 
tract urothelial carcinoma were used as controls. This study was approved by the 
Institutional Review Board (Comissão de Ética para a Saúde) of Portuguese Oncology 
Institute of Porto (CES IPO: 372/2017). 
 
CHEMICALS 
 Sodium L-lactate (L7022-5G; Sigma-Aldrich, Germany) was dissolved in sterile 
distilled water (B. Braun, Germany) to a 1M stock solution and stored at 4ºC until used. 
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 NAM (Sigma-Aldrich, Germany) was dissolved in sterile distilled water to a 400mM 
stock solution and stored at 4ºC until used. From this, a 20mM intermediate stock solution 
was obtained. 
 CHC (Sigma-Aldrich, Germany) was dissolved in dimethyl sulfoxide (DMSO; Sigma-
Aldrich, Germany) to a 3M stock solution, from which intermediate stock solutions (0.1-
1.5M) were prepared and stored at -20ºC until used. 
 Working solutions were freshly prepared in complete RPMI-1640 Medium. For 
working solutions of CHC, DMSO concentration did not exceed 1%. Control condition for 
CHC was performed with 1% DMSO in complete RPMI-1640 Medium. 
 
LACTATE SUPPLEMENTATION 
 HKC-8, HK-2, 769-P, Caki-1, Caki-2 and ACHN cell lines were exposed to different 
lactate conditions. Cells were plated in 25cm3 culture flasks in complete RPMI-1640 Medium 
at an optimal density, to obtain an 80-90% of confluence at ending timepoint. After cells’ 
exposure to 10mM or 20mM lactate in complete RPMI-1640 medium for 48h, the cultured 
medium was collected to perform lactate and glucose quantification, RNA and protein were 
extracted (Figure 13). For each condition, four independent replicates were performed. 
 
 
Figure 13. Lactate supplementation. The 6 kidney cell lines (HKC-8, HK-2, 769-P, Caki-1, Caki-2 and ACHN) 
were exposed to lactate 10 and 20mM for 48h. After, the cultured medium was collected, and RNA and protein 
were extracted. Abbreviations: ccRCC – Clear cell renal cell carcinoma, CTR – Control, Lac – Lactate; pRCC – 
Papillary renal cell carcinoma. Lameirinhas A. unpublished. 
 
CONDITIONED MEDIUM 
 Complete RPMI-1640 medium was used to culture 769-P, Caki-1, Caki-2 and ACHN 
cells in during 24h, 48h and 72h. After this period, the CM was collected, centrifuged and 
stored at -80ºC until use. Then, lactate and glucose from each condition mediums were 
quantified. 
 The two human renal proximal tubule epithelial cell lines HKC-8 and HK-2 were 
seeded in 25cm3 culture flasks in complete RPMI-1640 Medium at the same density used 
for lactate exposure. Then, culture medium was replaced by a combination of 72h CM from 
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tumor cell lines at 72h with complete Eagle’s MEM (Biochrom, MERK, Germany), in a 2:1 
ratio, using Eagle’s MEM as control condition. After 48h, the cultured medium was collected 
for lactate and glucose quantification, and RNA and protein extraction was performed 
(Figure 14). For each condition, four independent replicates were performed. 
 
 
Figure 14. CM. Conditioned medium from renal cell carcinoma lines were collected after 24h, 48h and 72h of 
culture, and the lactate and glucose levels were quantified. The 2 normal kidney cell lines (HKC-8 and HK-2) 
were exposed to a combination of 72h conditioned mediums tumor cell lines and complete Eagle’s MEM, in a 
2:1 ratio. 48h after, the cultured medium was collected, and RNA and protein were extracted. Abbreviations: 
CM – Conditioned medium, CTR – Control, RCC – Renal cell carcinoma. Lameirinhas A. unpublished. 
 
SIRTUINS INHIBITION 
 NAM is a noncompetitive inhibitor of SIRTs activity. This compound interacts with a 
catalytic intermediate preventing deacetylation through a base-exchange reaction. 
 The six kidney cell lines were plated in 25cm3 culture flasks in complete RPMI-1640 
Medium and, after cell adhesion, 200µM NAM was added to promote SIRTs inhibition, and 
RNA and protein extraction was performed 24h later (Figure 15). For control and treated 
conditions, four independent replicates were performed. 
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Figure 15. SIRTs inhibition. The 6 kidney cell lines (HKC-8, HK-2, 769-P, Caki-1, Caki-2 and ACHN) were 
treated with NAM 200µM for 24h, and then RNA and protein were extracted. Abbreviations: ccRCC – Clear cell 
renal cell carcinoma, CTR – Control, NAM – Nicotinamide, pRCC – Papillary renal cell carcinoma. Lameirinhas 
A. unpublished. 
 
MONOCARBOXYLATE TRANSPORTERS INHIBITION 
 CHC is a competitive MCTs inhibitor that competes with the substrate binding site, 
blocking lactate transport.  
 CHC half maximal inhibitory concentration (IC50) value (drug concentration that 
correspond to 50% of cell viability/growth inhibition) was determined for the six kidney cell 
lines by plating the cells at a density of 2x104 cell/mL in 96-well plates, in complete RPMI-
1640 Medium and incubated at 37ºC, 5% CO2. Then, the cells were treated with a 1-15mM 
range of CHC concentrations in complete RPMI-1640 Medium during 48h. The respective 
controls were performed with the corresponding 1% DMSO. The effect of CHC on cell 
growth was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenultetrazolium (MTT) assay 
(Sigma-Aldrich, Germany). 
 Cells were plated in 25cm3 culture flasks and adhered overnight in complete RPMI-
1640 Medium. Then, cells were treated with the corresponding IC50/2 CHC value, or in a 
combination with 20mM lactate, during 48h, and the cultured medium was collected to 
perform lactate and glucose quantification. RNA and protein extraction was performed 
(Figure 16). For each condition, four independent replicates were performed. 
 
 
 
MATERIAL AND METHODS | 33 
 
Figure 16. MCTs inhibition. The 6 kidney cell lines (HKC-8, HK-2, 769-P, Caki-1, Caki-2 and ACHN) were 
treated with IC50/2, or in a combination of IC50/2 and 20mM Lac, during 48h. Then, the cultured medium was 
collected, and RNA and protein were extracted. Abbreviations: ccRCC – Clear cell renal cell carcinoma, CHC – 
Alpha-cyano-4-hydroxycinnamate, CTR – Control, Lac – Lactate, pRCC – Papillary renal cell carcinoma. 
Lameirinhas A. unpublished. 
 
EXTRACELLULAR GLUCOSE AND LACTATE QUANTIFICATION  
 The levels of extracellular glucose and lactate were quantified in the culture medium 
collected at the end of the experiments and in the CM using a colorimetric kit (Spinreact, 
Spain).  
 The glucose is oxidized by glucose-oxidase (GOD) to gluconic acid and hydrogen 
peroxide (H2O2). Then, the peroxidase (POD) metabolizes the H2O2 that is converted in a 
quinone compound. The glucose concentration is directly proportional to the intensity of the 
color.  
 
 According to the manufacturer’s, 2µL of each sample was mixed with 100µL of 
working solution in a 96-well plate. Then, the samples were incubated during 20min at room 
temperature. An automated microplate reader (Fluostar Omega, BMG Labtech, Germany) 
at 490nm was used to measure the absorbance. 100µL of working solution alone was used 
as black to correct the optical density (OD) values. Calibration curve with a range of glucose 
concentrations was used to calculate the glucose levels in the samples. Results are 
expressed in glucose g/L. 
 The lactate is oxidized by lactate oxidase (LO) to pyruvate and hydrogen peroxide 
(H2O2). Then, the POD metabolizes the H2O2 that is converted in a red quinone compound.  
The lactate concentration is directly proportional to the intensity of the red color. 
H2O2 + Phenol + 4-Aminophenazone 
POD 
Quinone + H2O 
Β-D-Glucose + O2 + H2O
  
GOD 
Gluconic acid + H2O2 
L-2H2O2 + 4-Aminophenazone + 4-Cholophenol 
POD 
Quinone + H2O 
L-Lactate + O2 + H2O  
LO 
Pyruvate + H2O2 
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 According to the manufacturer’s, 2µL of each sample was mixed with 200µL of 
working solution in a 96-well plate. Then, the samples were incubated during 10min at room 
temperature. An automated microplate reader (Fluostar Omega, BMG Labtech, Germany) 
at 490nm was used to measure the absorbance. 200µL of working solution alone was used 
as black to correct the OD values. Calibration curve with a range of lactate concentrations 
was used to calculate the lactate levels in the samples. Results are expressed in lactate 
mM.  
 
RNA EXTRACTION, cDNA SYNTHESIS AND QUANTITATIVE REVERSE 
TRANSCRITION PCR 
 RNA extraction was performed using the ribozol reagent method. TripleXtractor 
(GRiSP®, Portugal) was added to the cell pellets, and these were dissociated using a 
needle. After a 5min incubation at room temperature, chloroform (VWR Chemicals, USA) 
was added, and the samples were vortexed and incubated for 3min at room temperature 
before being centrifuged at 10600rpm for 15min. The aqueous phase containing RNA was 
transferred to a RNase-free tube, and isopropanol (Millipore, Germany) was added. The 
samples were incubated 10min at room temperature and centrifuged at 13000rpm for 10 
min, to RNA precipitation. Finally, the RNA pellets were washed two times using 75% 
ethanol and, after dry, the pellets were eluted in RNA storage solution. 
 The RNA concentration and purity ratio were determined using the NanoDrop Lite 
Spectrophotometer (Nanodrop Technologies, USA), and the reverse transcription was 
performed from 1000ng of RNA using RevertAid RT kit (ThermoScientific Inc., USA), 
according the manufacturer procedures. At the end, the cDNA was eluted in of distilled 
water to obtain a final concentration of 100ng in 200µL.  
  Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was 
performed in 384-well plates LightCycler480II (Roche Diagnostics, Germany) using 4.5µL 
of diluted cDNA, 5µL of Xpert Fast SYBER Mastermix Blue (GE22.2501; GRiSP®, Portugal) 
and 0.3-0.5µL of specific primers described in Table 2, at a final volume of 10µL per well. 
All the samples were run in triplicates. 
 MCTs, VHL and HIF-1 transcript levels was determined in all kidney cell lines. For 
each gene, relative expression levels were calculated as the ratio between the target gene 
mean quantity and beta- glucuronidase (β-GUS), housekeeping gene, mean quantity (Gene 
Expression Level = Gene Mean Quantity / β-GUS Mean Quantity). 
 The mRNA levels of HDACs, SIRTs, EMT markers, senescence markers and tumor 
protein p53 (TP53) were also evaluated in the cells exposed to lactate, to CM, NAM and 
CHC. The transcript levels were evaluated using ΔΔCt method, where -GUS 
(housekeeping gene) was used as a reference gene to normalize obtained results. 
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Table 2. Primer used in RT-qPCR 
Gene Forward sequence (5’-3’) Reverse sequence (5’-3’) 
T 
annealing / 
Primer 
volume 
CD44 TGGTTGCTTCAAGGACACAT GCAAATGCTCTGTTGCAGTG 60ºC / 0.3µL 
CDH1 CTTTGACGCCGAGAGCTACA AAATTCACTCTGCCCAGGACG 64ºC / 0.5µL 
CDH2 GTGCCATTAGCCAAGGGAATTCAGC GCGTTCCTGTTCCACTCATAGGAGG 60ºC / 0.5µL 
CDKN1A TGCCGAAGTCAGTTCCTTGT  GTTCTGACATGGCGCCTCC  60ºC / 0.5µL 
GLB1 TCCACATCATGGTCCTCAGA GAAGATGGCTGGGCTGAA 60ºC / 0.5µL 
HDAC1 CCAAGTACCACAGCGATGAC TGGACAGTCCTCACCAACG 60ºC / 0.5µL 
HDAC2 CCTCATAGAATCCGCATGACCCATAAC AGACATGTTATCTGGTCTTATTGACCGTAG 60ºC / 0.3µL 
HDAC3 GCTTTGGCTTCCCTCTAGGT GCTTTGGCTTCCCTCTAGGT 60ºC / 0.5µL 
HIF-1 CAAGAACCTACTGCTAATGCCACC GTATGTGGGTAGGAGATGGAGATG 64ºC / 0.5µL 
LMNB1 CGACCAGCTGCTCCTCAACTAT TTCTCGAAGCTTGATCTGGGC 60ºC / 0.3µL 
MCT1 CATGCCACCACCAGCGAAG TGACAAGCAGCCACCAACAATC 60ºC / 0.3µL 
MCT4 CCATGCTCTACGGGACAGG GCTTGCTGAAGTAGCGGTT 60ºC / 0.3µL 
MMP1 GCTAACCTTTGATGCTATAACTACGA GGATTTGTGCGCATGTAGAA 62ºC / 0.5µL 
MMP10 AGTTTGGCTCATGCCTACCC TTGGTGCCTGATGCATCTTCT 62ºC / 0.5µL 
SIRT1 GCGGGAATCCAAAGGATAAT GCACCTAGGACATCGAGGAA 60ºC / 0.5µL 
SIRT2 GACAACACAGGCAGTGGCTA CAGCTACTTGGGAGGCTGAG 60ºC / 0.3µL 
SIRT3 AAGTGGGGCGCTTAATAGGT CACAGCAGCAAAGGAAACAG 62ºC / 0.3µL 
SIRT4 CAGCAAGTCCTCCTCTGGAC CCAGCCTACGAAGTTTCTCG 60ºC / 0.5µL 
SIRT5 CCAGATTGTCCCAAGTCGAT TCTGTTCTGTTCCACCGTGA 60ºC / 0.3µL 
SIRT6 CCAAGTTCGACACCACCTTT TGGCACATTCTTCCACAAAC 60ºC / 0.5µL 
SIRT7 ACGAATGGGGTGTAGTAGCC TCACATGCCTGATCCTTGTC 60ºC / 0.5µL 
TP53 CGCTTCGAGATGTTCCGAGA CTTCAGGTGGCTGGAGTGAG 60ºC / 0.3µL 
VHL TCTCTCAATGTTGACGGACAGC GATCTTCGTAGAGCGACCTGAC 60ºC / 0.3µL 
β-GUS CTCATTTGGAATTTTGCCGATT CCGAGTGAAGATCCCCTTTTTA 60ºC / 0.5µL 
 
DNA EXTRACTION, SODIUM BISULFITE MODIFICATION AND QUANTITATIVE 
METHYLATION-SPECIFIC PCR 
 The DNA extraction was performed using the phenol-chloroform method. After cell 
collecting, SE buffer [(75mM NaCl and 25mM ethylenediamine tetraacetic acid (EDTA)], 
10% sodium dodecyl sulfate (SDS) and proteinase K at 20mg/mL concentration 
(NZYTECH, Portugal) were added, and the samples were incubated at 55ºC in agitation. 
ΔΔCt = (ΔCt Target Gene – ΔCt Reference Gene) – (ΔCt Target Gene – ΔCt Reference Gene) 
CTR Cells Treated Cells 
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Additional proteinase K [20mg/mL (NZYTECH, Portugal)] was added at twice a day until 
complete digestion was achieved. After complete digestion, the samples were transferred 
to previously centrifuged Phase Lock Light tubes (5 Prime, Germany) and phenol-
chloroform solution at pH=8 (Sigma-Aldrich, USA) was added. The samples were 
centrifuged 20min at 4000rpm, and the aqueous phase containing the DNA was collected. 
In order to allow DNA precipitation, 2 volumes (of original amount of aqueous phase) of 
absolute ethanol (Merck, Germany) and 1/3 volume of 7.5M Ammonium acetate (Sigma-
Aldrich, Germany) were added to the aqueous phase, and the samples were incubated 
overnight at -20°C. Then, samples were centrifuged at 13,000rpm for 20min and the DNA 
pellets were washed two times using 70% ethanol. After dry, the pellets were eluted in sterile 
distilled water. 
 The DNA concentration and purity ratio were assessed using the NanoDrop Lite 
Spectrophotometer (Nanodrop Technologies, USA), sodium bisulfite conversion was 
performed from 1000ng of DNA using the EZ DNA Methylation-GoldTM Kit (Zymo Research, 
USA) according to the manufacturer’s instructions. At the end, the modified DNA was eluted 
in 60µL of sterile distilled water.  
 Sodium bisulfite treatment was performed to study the methylation status by PCR-
based methods. In this technique, the unmethylated cytosines are converted into uracil 
residues through a process of sulphonation, deamination and desulphonation, while 5mC 
remains unaltered (Figure 17).  
 
 
Figure 17. Sodium bisulfite modification diagram. The unmethylated cytosines are converted into uracil 
residues, while 5-methylcytosines remains unaltered. Lameirinhas A. unpublished. 
 
 Quantitative methylation-specific PCR (qMSP) was performed to determine MCT1, 
MCT4 and VHL promoter genes methylation levels in all kidney cell lines. In qMSP, primers 
with CpGs for each target gene, were designed specifically for bisulfite-converted DNA, 
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which allows the specific amplification of methylated DNA. The reactions were performed 
in 384-well plates LightCycler480II (Roche Diagnostics, Germany) using 1µL of modified 
DNA, 5µL of Xpert Fast SYBER Mastermix Blue (GE22.2501; GRiSP®, Portugal) and 0.4-
0.5µL of specific primers described in Table 3, at a final volume of 10µL per well. All the 
samples were run in triplicates. For each gene, relative methylation levels were calculated 
as the ratio between the target gene mean quantity and beta-actin (β-ACT), housekeeping 
gene, mean quantity (Gene Expression Level = Gene Mean Quantity / β-ACT Mean 
Quantity). 
 
Table 3. Primer used in qMSP 
Gene Forward sequence (5’-3’) Reverse sequence (5’-3’) 
T annealing 
/ Primer 
volume 
MCT1 AAGTAAACGAGGTAGCGAGC ACGAAACACCGTAAAATCC 62ºC / 0.4µL 
MCT4 CGTTTTCGAGTTTCGAGTC ACGCTACCGTAATTACCGAC 64ºC / 0.5µL 
VHL TGGAGGATTTTTTTGCGTACGCG CGAACCGAACGCCGCGAA 62ºC / 0.5µL 
β-ACT TGGTGATGGAGGAGGTTTAGTAAGT ACCAATAAAACCTACTCCTCCCTTAA 60ºC / 0.4µL 
 
PROTEIN EXTRACTION AND QUANTIFICATION 
 Total protein was extracted from all untreated cell lines and from cells exposed to 
lactate, CM, NAM and CHC. Cells were scrapped from the culture flasks, homogenized in 
Kinexus lysis buffer (Kinexus Bioinformatics, Canada) with TritonTM X-100 (Sigma-Aldrich, 
Germany) supplemented with proteases inhibitors cocktail and sonicated in 5 cycles of 20 
seconds ON and 20 seconds OFF. After that, the samples were centrifuged at 13,300 rpm 
for 30min at 4ºC and the supernatant was collected. Then, the protein concentration was 
determined using the Pierce BCA Protein Assay Kit (Thermo Scientific Inc., USA), according 
to the manufacture’s procedures.   
 
WESTERN BLOT 
 30µg total protein was separated in 8-12.5% polyacrylamide gel by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred into an immunoblot 
nitrocellulose membrane (Bio-Rad, USA) in a 25mM Tris-base/ glycine buffer using a Trans-
Blot Turbo Transfer system (Bio-Rad, USA). Membranes were blocked with 5% milk or 
bovine serum albumin (BSA; Santa Cruz, USA) in tris-buffer saline (TBS)/0.1% Tween 
(TBS/T pH=7.6) for 1h at room temperature. Then, the membranes were incubated 
overnight at 4°C with specific primary antibodies for SIRT1, SIRT3, SIRT6, H3ac, H4ac, 
H3K9ac and H4K16ac. After incubation, the membranes were washed in TBS/T and 
incubated with secondary antibody coupled with horseradish peroxidase (Bio-Rad, USA) 
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diluted 1:3000, for 1h at room temperature. The bounds were visualized by 
chemiluminescence (Clarity WB ECL substrate, Bio-Rad, USA). Western blot (WB) 
quantification results using band densitometry analysis was performed using the ImageJ 
software (version 1.6.1, National Institutes of Health). β-ACT, H3 and H4 were used to 
loading control. The primary antibodies dilutions are described in Table 4. 
 
Table 4. Primary antibodies used in WB and IF 
Primary 
antibody 
Company 
Western-Blot 
dilution 
IF dilution 
Second antibody 
specie 
Acetylated-
Lysine 
Cell Signaling, 
#9441 
n.a. 1:250 Anti-rabbit 
H3 Abcam, ab1791 
1:5000,  
5% BSA in TBS/T 
n.a. Anti-rabbit 
H3ac 
Millipore,  
06-599 
1:5000,  
5% BSA in TBS/T 
1:250 Anti-rabbit 
H3K9ac 
Millipore, 
SC20058 
1:500,  
5% BSA in TBS/T 
1:150 Anti-rabbit 
H4 Abcam, ab10158 
1:1000,  
5% BSA in TBS/T 
n.a. Anti-rabbit 
H4ac 
Millipore,  
06-598 
1:500,  
5% BSA in TBS/T 
1:250 Anti-rabbit 
H4K16ac 
Cell Signaling, 
#13534 
1:750,  
5% BSA in TBS/T 
1:150 Anti-rabbit 
SIRT1 Abcam, ab32441 
1:1000,  
5% milk in TBS/T 
1:250 Anti-rabbit 
SIRT3 
Cell Signaling, 
#5490 
1:1000,  
5% BSA in TBS/T 
1:250 Anti-rabbit 
SIRT6 Abcam, ab88494 
1:1000,  
5% milk in TBS/T 
1:250 Anti-rabbit 
β-Actin 
Sigma-Aldrich, 
A1978 
1:10,000, 
5% milk in TBS/T 
n.a. Anti-mouse 
IF – Immunofluorescence; n.a. – not applicable 
 
IMMUNOFLUORESCENCE AND IMMUNOCYTOCHEMISTRY 
 Immunofluorescence (IF) was performed to assess the protein expression and 
localization of SIRT1, SIRT3, SIRT6, H3ac, H4ac, H3K18ac, H4K16ac and Acetylated-
Lysine in cells treated with lactate, CM, NAM and CHC. Immunocytochemistry (ICC) was 
performed to assess the protein expression and cellular localization of HIF-1, VHL, MCT1 
and MCT4 in all kidney cell lines and also in cells treated with lactate or CM. 
 The cells were seeded in cover slips at 2,500 cells/well, overnight. Then, the culture 
medium was removed and replaced for complete culture medium (RPMI-1640 Medium or 
Eagle’s MEM) supplemented with lactate, CM, NAM or CHC for 48h.  
 For IF, cells were fixed 10min in 4% paraformaldehyde (PFA, Santa Cruz, USA), 
following cell permeabilization with TritonTM X-100 0,25% in 1x phosphate-buffer saline 
(PBS) during 15 min. Then, cells were blocked with 5% BSA in 1x PBS, for 30min and 
incubated with primary antibodies diluted in 5% BSA in 1x PBS (Table 4), overnight at room 
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temperature. In the next day, the cells were incubated with secondary antibody anti-rabbit 
immunoglobulin G (IgG) tetramethylrhodamine (TRITC) (T6778, Sigma-Aldrich, Germany) 
or anti-rabbit IgG-fluorescein isothiocyanate (FITC) (Alexa Fluor TM 488, A11008; 
Invitrogene, USA), for 1h at room temperature. In the next day, cells were stained with 4’,6-
diamidino-2-phenylindole (DAPI; AR1176, BOSTER Biological Technologies, China) in 
mounting medium. Pictures were taken in a fluorescence microscope Olympus IX51 with a 
digital camera Olympus XM10 using CellSens software (Olympus, Japan) (200x 
magnification). 
 For ICC, cells were fixed 15min in 4% PFA. For HIF-1 and VHL proteins, cell 
permeabilization was performed for 15min with TritonTM X-100 0,25% in 1x PBS. Novolink™ 
Max Polymer Detection System (Leica Biosystems, Germany) was used for HIF-1 and 
VHL, and UltraVision Detection System (Large Volume Anti-Polyvalent, HRP; Thermo 
Scientific Inc., USA) for MCTs. After endogenous peroxidase activity inactivation by 3% 
hydrogen peroxide (H2O2; Millipore, Germany) in methanol, cells were blocked and 
incubated overnight with primary antibody (Table 5), at room temperature, followed by post 
primary block, polymer and 3,3′-diaminobenzidine (DAB; Sigma-Aldrich™, Germany). In the 
final step, cells were counterstained with hematoxylin and mounted in aqueous mounting 
medium (Aquatex®, Merck, Germany). Pictures were taken in a microscope Olympus BX41 
with a digital camera Olympus U-TV0.63XC using CellA software (200x magnification).  
 
Table 5. Primary antibodies used in ICC 
Primary 
antibody 
Company ICC dilution 
Second antibody 
specie 
HIF-1 Cell Signaling, #36169 1:250 Anti-rabbit 
MCT1 
Santa Cruz, 
 sc-365501 
1:250 Anti-mouse 
MCT4 
Santa Cruz,  
sc-376140 
1:500 Anti-mouse 
VHL Cell Signaling, #68547 1:300 Anti-rabbit 
ICC – Immunocytochemistry 
 
SIRTUINS ACTIVITY ASSAY 
 SIRTs enzymatic activity present on total protein extracts from cells exposed to 
lactate, CM, NAM and CHC was determined using the colorimetric Universal SIRT Activity 
Assay Kit (ab156915, Abcam Inc., Boston, MA, USA). This assay is based on SIRT 
activity/inhibition measurement by directly detecting SIRT-converted deacetylated products. 
 According to the manufacturer’s, 5ng of total protein extracts were incubated with 
SIRT substrate, SIRT cofactor (NAD+), HDACs Inhibitor and assay buffer, during 90min at 
MATERIAL AND METHODS | 40 
37ºC. Then, the capture antibody was added and incubated at room temperature for 60min. 
After, the signal was enhancing by detection antibody incubation for 30min, at room 
temperature. Then, the absorbance was read in an automated microplate reader (Fluostar 
Omega, BMG Labtech, Offenburg, Germany) at 450nm with an optical reference 
wavelength of 655nm (Figure 18). 
 
 
Figure 18. SIRTs activity assay diagram. Sirtuins activity/inhibition were measured by directly detecting SIRT-
converted deacetylated products. Abbreviation: HDAC – Histone deacetylase, NAD – Nicotinamide adenine 
dinucleotide, RT – Room temperature, SIRT – Sirtuin. Lameirinhas A. unpublished. 
 
 SIRT substrate, SIRT cofactor and assay buffer was used as blank to correct the 
OD values, and the SIRT activity calculation was performed using following formula, where 
protein amount (PA) corresponds to 5µg of total protein extract added at the first reaction 
step, and incubation time (IT) corresponds to 90min after the first reaction step: 
 [𝑺𝑰𝑹𝑻 𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚 (𝑶𝑫/𝒎𝒊𝒏/𝒎𝒈)]  =  
𝑺𝒂𝒎𝒑𝒍𝒆 𝑶𝑫 − 𝑩𝒍𝒂𝒄𝒌 𝑶𝑫
𝑷𝑨 (µ𝒈) × 𝑰𝑻 (𝒎𝒊𝒏)
= 𝟏𝟎𝟎𝟎 
 
CELL VIABILITY AND PROLIFERATION ASSAYS 
 The effects on cell viability was assessed by MTT assay (Sigma-Aldrich, Germany). 
MTT assay is a direct measure of cell viability, once this technique allows to evaluate cell 
mitochondrial activity. Viable cells are able to incorporate MTT solution and the 
mitochondrial enzyme succinate-dehydrogenase convert them into a purple colored 
formazan product.  
 To determine differences in cell proliferation the Cell Proliferation ELISA BrdU assay 
(Roche Applied Sciences, Germany) was used. This is a colorimetric immunoassay where 
5-bromo-2’-deoxyuridine (BrdU), a pyrimidine analog, is incorporated in placed of pyrimidine 
into the newly synthesized DNA. The quantity of BrdU incorporated into cells is directly 
correlated to the number of proliferating cells. 
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 Cells were plated into 96-well plates in complete RPMI-1640 Medium at 2000 
cells/well and incubated overnight. Then, cells were treated with lactate, CM, NAM or CHC, 
during 48H. MTT and BrdU assays were performed at 0h and at treatments’ ending.  
 In MTT assay, the culture medium was removed, and cells were incubated during 
1h at 37ºC with 5µg/mL MTT solution in complete culture medium. After that, formazan 
crystals formed were dissolved in DMSO and spectrophotometric measurement was done 
at 540nm (reference wavelength: 655nm) in a microplate reader (Fluostar Omega, BMG 
Labtech, Germany). DMSO was used as blanks to correct the OD values, and OD obtained 
for 48h was normalized for the 0h time point.  
 For BrdU assay, cells were incubated with 20µM BrdU labeling solution for 12h. After 
removing labeling medium, cells were fixed for 30min at room temperature with FixDenat 
solution. This solution induces DNA denaturation necessary to allow conjugated antibody 
binding to the incorporated BrdU. Then, FixDenat was removed, and Anti-BrdU-POD 
antibody (dilution 1:100) was added to detect the incorporated BrdU in DNA. After 90min, 
at room temperature, the antibody was removed, and cells were washed 3 times with 1X 
PBS. To detect the immune complex formed, substrate solution was added and incubated 
for 5-10min, until color development. Then, the reaction was stopped with 1M H2SO4 added 
to each well, and the reaction product was quantified in a microplate reader (Fluostar 
Omega, BMG Labtech, Germany) by measuring absorbance at 450nm (reference 
wavelength: 690nm). The OD values obtained for 48h was normalized for the 0h time point.  
 For both assays, at least three independent experiments were performed, each one 
in triplicate. 
 
WOUND HEALING ASSAY 
 Wound healing assay was performed to determine the in vitro cell migration in cells 
expos to lactate, CM, NAM and CHC. 
 Cells were seeded (6-well plate) in complete RPMI-1640 Medium at an optimal 
density to obtain at least 95% of confluence in the next 24h, and incubated at 37ºC, 5% 
CO2. In the next day, the culture medium was removed, and two “wounds” were made by 
manual scratching with a 200 µL pipette tip for each condition. Then, the wells were washed 
with 1X PBS in order to remove detached cells in wound, and incubated with complete cell 
medium (RPMI-1640 Medium or Eagle’s MEM) supplemented with lactate, NAM or CHC, 
or for CM. The wound areas were photographed in two specific sites at 40x magnification 
using an Olympus IX51 inverted microscope equipped with an Olympus XM10 Digital 
Camera System. The photos were taken at regular time points (between 0 and 48h) until 
wound closure. The relative migration distance (5 measures by wound) was calculated with 
the following formula: relative migration distance (%) = (A–B)/C x100, where A is the width 
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of cell wound at 0h incubation, B is the width of cell wound after specific hours of incubation, 
and C is the width mean of cell wound for 0h of incubation. For relative migration distance, 
the results were analyzed using the beWound - Cell Migration Tool (Version 1.5) (developed 
by A.H.J. Moreira, S. Queirós and J.L. Vilaça, Biomedical Engineering Solutions Research 
Group, Life and Health Sciences Research Institute - University of Minho; available at 
http://www.besurg.com/sites/default/files/beWoundApp.zip). At least three independent 
experiments were performed.  
 
INVASION ASSAY 
 Cell invasion was evaluated by using 24-well BD BioCoat Matrigel Invasion 
Chambers, with 8µm pore size membranes (BD BioSciences, USA). These invasion 
chambers allow to compare the in vitro cells invasive behavior in specific conditions.  
 After BD Matrigel Chambers rehydration between 30min and 2h with serum free 
culture media at 37ºC, cells at a density of 15,000 cells/insert were seeded in complete 
culture medium supplemented with lactate or CM and incubated during 24h at 37ºC in 5% 
CO2. Then, the non-invading cells were removed by with swab and invaded cells were 
methanol fixed, DAPI stained and counted in a fluorescence microscope Olympus IX51 with 
a digital camera Olympus XM10 using CellSens software. The invasion was calculated as 
% of cell invasion normalized for the control condition. 
 
IMMUNOHISTOCHEMISTRY 
 IHC for SIRT1, SIRT6 and HIF-1 was performed using the Novolink™ Max Polymer 
Detection System (Leica Biosystems, Germany) in 3μm thick sections from formalin-fixed 
and paraffin-embedded tissues. After deparaffinization and rehydration, antigen retrieval 
was accomplished by microwave at 800W for 20min in specific buffer for each protein (Table 
6). After the endogenous peroxidase activity inactivation in 3% H2O2 solution for 10min, 
slides were blocked with horse serum diluted in antibody dilution at 1:50 for 20min and 
incubated overnight with primary antibody (Table 6). Then, the slides were incubated 30min 
with post primary block, followed 30min with polymer. The DAB (Sigma-Aldrich™, 
Germany) was used as a chromogen and slides were counterstained with hematoxylin and 
mounted with Entellan® (Merck-Millipore, Germany). A positive control was included (Table 
6).  
 Immunoexpression was evaluated semi-quantitatively by a pathologist and 
categorized according extension (between 0-100%) and intensity (between 0-3). Only 
nuclear expression was considered. The score for extension was: score 0 (<1% of 
immunoreactive cells), score 1 (1-10% of immunoreactive cells), score 2 (10-50% of 
immunoreactive cells) and score 3 (>50% of immunoreactive cells). The score for intensity 
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was: score 0 (absent immunoexpression), score 1 (immunoexpression less intense than in 
normal tissue), score 2 (immunoexpression similar to normal tissue) and score 3 
(immunoexpression more intense than in normal tissue). The extension and intensity scores 
were combined and a final score  3 was defined as cut-off to define positive cases. Pictures 
were taken in a microscope Olympus BX41 with a digital camera Olympus U-TV0.63XC 
using CellA software.  
 
Table 6. Primary antibodies used in IHC 
Primary 
antibody 
Company Positive Control Antigen Retrieval 
Primary antibody 
dilution 
HIF-1 
Cell Signaling, 
#36169 
ccRCC 
EDTA buffer 
(1mM, pH=8) 
1:500  
overnight RT 
SIRT1 
Abcam,  
ab32441 
Colon 
EDTA buffer 
(1mM, pH=8) 
1:350  
overnight RT 
SIRT6 
Abcam,  
ab88494 
Colon 
Citrate buffer 
(10mM, pH=6) 
1:500  
overnight RT 
ccRCC – Clear Cell Renal Cell Carcinoma; RT – Room temperature 
 
STATISTICAL ANALYSIS 
 Statistical analysis was performed using the GraphPad Prim 6.0 software 
(GraphPad Software Inc., USA). Non-parametric Mann-Whitney U test were used to 
compare two groups. For comparison between three or more groups, non-parametric 
Kruskal-Wallis test was used, followed by Mann-Whitney U test for pairwise comparisons 
and Bonferroni’s correction, when applicable. Differences in SIRTs and HIF-1 
immunoexpression between normal kidney, ccRCC and pRCC tissues was assessed by 
Chi-square or Fisher’s exact test. 
 P-values were considered statistically significant when inferior to 0.05. Significance 
is shown vs. the respective control and depicted as follows: *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 and nsp> 0.05 (non-significant). 
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LACTATE DECREASES SIRTUINS EXPRESSION CONTRIBUTING TO METABOLIC 
REPROGRAMING AND INCREASED TUMOR AGGRESSIVENESS IN RENAL CELL 
CARCINOMAS 
 The effect of lactate was assessed in one primary and one metastatic ccRCC (769-
P and Caki-1, respectively) and pRCC (Caki-2 and ACHN, respectively) cell lines exposed 
to two lactate concentrations (10 and 20mM) that simulated the levels produced by 
glycolytic cells and released to tumor microenvironment. At molecular level, lactate did not 
affect HDACs Class I (HDAC1, HDAC2 and HDAC3) expression levels in any of the tested 
cell lines (Figure 19A), whereas SIRT1, SIRT3 and SIRT6 expression levels decreased 
significantly in all cell lines tested, with exception of ACHN (Figure 19B). 
 
 
Figure 19. Lactate effect on HDACs Class I and III expression in kidney tumor cell lines. Expression of 
HDAC1-3 (A) and SIRT1-SIRT7 (B) in kidney tumor cell lines after treatment with 10mM and 20mM of lactate, 
by RT-qPCR; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared to control; results are 
representative of four independent experiments with mean±SD, each of them in triplicates. Abbreviations: CTR 
– Control, Lac – Lactate. 
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 The inhibitory effect of lactate in SIRTs was also observed at protein level for cells 
exposed to 20mM lactate (Figure 20A). Furthermore, a shift in SIRT1 protein localization 
(nucleus to cytoplasm) (Figure 20B), and a decrease in SIRTs activity was also disclosed 
(Figure 20C).  
 
 
Figure 20. Lactate decreases SIRTs expression in kidney tumor cell lines. Characterization of SIRT1, 
SIRT3 and SIRT6 expression in kidney tumor cell lines treated with 20mM lactate by western blot (A) and 
immunofluorescence (B), and of sirtuins activity (C). Results are compared to control and representative of four 
independent experiments with mean±SD, each of them in triplicates. Photograph taken in microscope Olympus 
IX51 with a digital camera Olympus XM10 (200x magnification). Abbreviations: C – Control, CTR – Control, L – 
20mM Lactate, Lac – Lactate. 
 
 Accordingly, 20mM lactate exposure increased acetylated-lysine levels (Figure 21A) 
as well as global histone H3 acetylation (Figure 21B-C) in the four RCC cell lines. 
Nonetheless, increased H4 global acetylation was only observed in 769-P and Caki-1 
(Figure 21B-C). Regarding specific aminoacidic residues, the effect was more pronounced 
in H3K9 and H4K16 acetylation levels (Figure 21D-E). 
RESULTS | 49 
 
Figure 21. Lactate increase histone acetylation in kidney tumor cell lines. Characterization of total 
Acetylated Lysine (A), global histone acetylation of histone H3 and H4 (B-C), and specific histone markers, 
H3K9 and H4K16 (D-E), in kidney tumor cell lines treated with 20mM lactate by immunofluorescence and 
western blot. Results are compared to control and representative of four independent experiments with mean, 
each of them in triplicates. Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 
(200x magnification). Abbreviations: C – Control, CTR – Control, L – 20mM Lactate. 
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 Additionally, and except for 769-P cells, increased HIF-1 nuclear protein levels 
were also observed in cells exposed to 20mM lactate (Figure 22A), which was paralleled 
by increased MCT1 expression, both in cell membrane and nucleus (Figure 22B). 
Furthermore, increased MCT4 membrane expression was also observed in 769-P and Caki-
1 (Figure 22C) cells exposed to lactate. 
  
 
Figure 22. Lactate increases HIF-1 and MCTs expression in kidney tumor cell lines contributing to 
glycolytic metabolism. Characterization of HIF-1 (A), MCT1 (B) and MCT4 (C) expression in kidney tumor 
cell lines treated with 20mM lactate, by immunocytochemistry. Photograph taken in microscope Olympus BX41 
with a digital camera Olympus U-TV0.63XC (200x magnification). Abbreviations: CTR – Control. 
 
 Phenotypically, lactate exposure did not significantly affect cell growth (Figure 23A) 
and cell proliferation (Figure 23B), with exception of Caki-1 (Figure 23B). Although 
differences were observed for TP53 gene expression levels in cells exposed to 20mM 
lactate, these did not reach statistical significance, suggesting a possible association with 
cell death (Figure 23C), that has to be confirmed in further studies. 
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 Conversely, lactate exposure increased cell migration capacity of all RCC cell lines 
(Figure 23D and Supplementary Figure 1A), for most of the timepoints. Indeed, in Caki-1 
and ACHN cells, migration capacity was only significantly increased at 36h and 48h. 
Accordingly, 769-P cells exposed to lactate increased 70% the cell invasion in matrigel 
membrane, and 25% in Caki-1 and Caki-2 cells (Figure 23E). In contrast, a 30% decrease 
in cell invasion was observed in ACHN cells exposed to lactate (Figure 23E). 
 
 
Figure 23. Lactate promotes cell aggressiveness in kidney tumor cell lines. Effect of 20mM lactate 
treatment in kidney tumor cell lines at cell growth (A) by MTT assay, cell proliferation (B) by BrdU assay, TP53 
expression (C) by RT-qPCR, cell migration (D) by wound-healing assay and cell invasion (E) by Matrigel 
Invasion Chambers. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to control; results are representative of four 
independent experiments with mean±SD, each of them in triplicates. Abbreviations: CTR – Control, Lac – 
Lactate. 
 
 Nonetheless, at molecular level, no consistent alterations were found for EMT 
markers in cells exposed to lactate (Figure 24). Indeed, only 769-P lactate exposed cell line 
displayed significantly increased CD44 expression levels compared to control. Moreover, 
although no significant effect was found for cadherin (CDH) 2 (mesenchymal marker) in cell 
lines treated with 10mM lactate, a significant decrease was observed with 20mM lactate 
(Figure 24). Additionally, 769-P and Caki-1 cells depicted decreased metalloproteinase 
(MMP) 1 expression levels, whereas MMP10 expression levels were significantly increased. 
Contrarily, expression levels of both MMPs were increased in Caki-2 and ACHN lactate 
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exposed cells, although statistical significance was only achieved for MMP1 expression in 
ACHN cells  
  
   
Figure 24. Lactate effect on EMT markers in kidney tumor cell lines. Expression of mesenchymal marker 
CDH2, and related-invasion cell markers (CD44, MMP1 and MMP10) in kidney tumor cell lines after treatment 
with 10mM and 20mM of lactate, by RT-qPCR; *p<0.05, **p<0.01 and ***p<0.001 compared to control; results 
are representative of four independent experiments with mean±SD, each of them in triplicates. Abbreviations: 
CTR – Control, Lac – Lactate. 
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TUMOR METABOLISM MODULATES EPIGENETIC LANDSCAPE OF NORMAL 
ADJACENT CELLS  
Lactate affects sirtuins regulation with consequent alterations on cell behavior of 
normal kidney cells 
 Similar to cancer cells, the two normal kidney cell lines (HKC-8 and HK-2) exposed 
to lactate displayed decreased SIRT1, SIRT3 and SIRT6 expression levels (Figure 25A). At 
protein level, SIRT1, SIRT3 and SIRT6 reduction was only observed in HK2 cell line, 
whereas HKC-8 cells only displayed SIRT1 expression downregulation (Figure 25B-C). 
Additionally, decreased SIRTs activity was observed in HK2 cells exposed to 20mM lactate 
(Figure 25D). Nevertheless, increased global acetylated-lysine (Figure 26A), acetylated H3 
and H4 (Figure 26B and D) and H4K16ac marks (Figure 26C and E) were found in both cell 
lines. 
 
 
Figure 25. Lactate induces SIRTs downregulation in normal kidney cell lines. Characterization of SIRT1, 
SIRT3 and SIRT6 expression in normal kidney cell lines treated with lactate by RT-qPCR (A), western blot (B) 
and immunofluorescence (C), and of sirtuins activity (D). Results are compared to control and representative of 
four independent experiments with mean±SD, each of them in triplicates. *p < 0.05, **p < 0.01 and ***p < 0.001. 
Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 (200x magnification). 
Abbreviations: C – Control, CTR – Control, L – 20mM Lactate, Lac – Lactate. 
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Figure 26. Lactate promotes histone acetylation in normal kidney cell lines. Characterization of total 
Acetylated Lysine (A), global histone acetylation of histone H3 and H4 (B and D), and specific histone markers, 
H3K9 and H4K16 (C and E), in normal kidney cell lines treated with 20mM lactate by immunofluorescence and 
western blot. Results are compared to control and representative of four independent experiments with mean, 
each of them in triplicates. Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 
(200x magnification). Abbreviations: C – Control, CTR – Control, L – 20mM Lactate. 
 
 Concerning cellular metabolism, a slight increase of nuclear HIF-1 was observed 
in cells treated with 20mM lactate  and a moderate intensification of MCT1 and MCT4 
expression was found in cell membrane of those cells (Figure 27). Furthermore, MCT1 
nuclear expression was also increased, particularly in HKC-8 cells (Figure 27B). 
 
 
Figure 27. Lactate promotes glycolytic metabolism in normal kidney cell lines. Characterization of HIF-1 
(A), MCT1 (B) and MCT4 (C) expression in normal kidney cell lines treated with 20mM lactate, by 
immunocytochemistry. Photograph taken in microscope Olympus BX41 with a digital camera Olympus U-
TV0.63XC (200x magnification). Abbreviations: CTR – Control. 
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 Despite no cell growth or proliferation changes have been found (Figure 28A-B, 
respectively), decreased cell death was verified at molecular level by evaluating TP53 
transcript (Figure 28C). Furthermore, cell migration was only significantly augmented in HK-
2 and HKC-8 cells at 12h and 24h, respectively (Figure 28D and Supplementary Figure 1B). 
Lastly, HKC-8 cells showed a 38% increase of invading cells compared to the control. In 
contrast, no significant alterations were found for HK-2 cells (Figure 28E). Additionally, 
lactate treatment was associated with CDH1 downregulation in HK-2 cells, whereas CDH2 
and CD44 were upregulated in HKC-8 cells. Both cell lines, showed increased expression 
levels of MMP 1 and MMP10 (Figure 29).  
 
 
Figure 28. Lactate contributes to cell aggressiveness in normal kidney cell lines. Effect of 20mM lactate 
treatment in normal kidney cell lines at cell growth (A) by MTT assay, cell proliferation (B) by BrdU assay, TP53 
expression (C) by RT-qPCR, cell migration (D) by wound-healing assay and cell invasion (E) by Matrigel 
Invasion Chambers. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to control; results are representative of four 
independent experiments with mean±SD, each of them in triplicates. Abbreviations: CTR – Control, Lac – 
Lactate. 
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Figure 29. Lactate effect on EMT markers in normal kidney cell lines. Expression of mesenchymal markers 
(CDH1 and CDH2), and related-invasion cell markers (CD44, MMP1 and MMP10) in normal kidney cell lines 
after treatment with 10mM and 20mM of lactate, by RT-qPCR; *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001 compared to control; results are representative of four independent experiments with mean±SD, 
each of them in triplicates. Abbreviations: CTR – Control, Lac – Lactate. 
 
Conditioned medium decreases sirtuins expression and promotes cell 
aggressiveness in normal kidney cells 
 The effect of lactate produced and exported by cancer cells in adjacent normal cells 
(HKC-8 and HK-2) epigenetic modulation was also tested by exposing normal cells to CM 
collected from those tumor cells after 24h, 48h and 72h of culture (Supplementary Figure 
2). Because the highest lactate levels were obtained in tumor cells’ CM at 72h, this condition 
was chosen to expose normal cells. 
 After 48h of normal kidney cell lines exposure to CM, only SIRT1 transcript levels 
were significantly decreased in HKC-8 cell line (Figure 30A) and both normal kidney cells 
lines display a significantly decreased at protein level (Figure 30B). Additionally, decreased 
SIRT1 and SIRT6 nuclear expression and cellular localization shift to cytoplasm was 
observed in HK-2 cells (Figure 30C). Although SIRTs activity was reduced in HK-2 cells, 
HKC-8 cells displayed the opposite trend (Figure 30D). Moreover, in agreement with 
previous results, increased global acetylated-lysine (Figure 31A), global histone acetylation 
(H3ac and H4ac) (Figure 31B) and (H3K9ac and H4K16ac) acetylation (Figure 31B) was 
found. 
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Figure 30. CM modulates SIRTs expression in normal kidney cell lines. Characterization of SIRT1, SIRT3 
and SIRT6 expression in normal kidney cell lines treated with conditioned medium from tumor cells, by RT-
qPCR (A), western blot (B) and immunofluorescence (C), and of sirtuins activity (D). Results are compared to 
control and representative of four independent experiments with mean±SD, each of them in triplicates. **p < 0.01 
and ***p < 0.001. Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 (200x 
magnification). Abbreviations: CTR – Control, CM – Conditioned medium. 
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Figure 31. CM increase histone deacetylation in normal kidney cell lines. Characterization of total 
Acetylated Lysine (A), global histone acetylation of histone H3 and H4 (B), and specific histone markers, H3K9 
and H4K16 (C), in normal kidney cell lines treated with conditioned medium from tumor cells, by 
immunofluorescence and western blot. Results are compared to control and representative of four independent 
experiments with mean, each of them in triplicates. Photograph taken in microscope Olympus IX51 with a digital 
camera Olympus XM10 (200x magnification). Abbreviations: CTR – Control, CM – Conditioned medium. 
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 Concerning cellular metabolism deregulation, increased HIF-1 nuclear protein 
levels (Figure 32A) and MCT1 and MCT4 plasma membrane expression (Figure 32B-C) 
was found in treated normal cell lines, suggesting a shift to glycolytic metabolism. 
Accordingly, MCT1 nuclear expression was also increased for most of the conditions 
(Figure 32B). 
 
 
Figure 32. CM increase HIF-1 and MCTs expression in normal kidney cell lines. Characterization of HIF-
1 (A), MCT1 (B) and MCT4 (C) expression in normal kidney cell lines treated with conditioned medium from 
tumor cells, by immunocytochemistry. Photograph taken in microscope Olympus BX41 with a digital camera 
Olympus U-TV0.63XC (200x magnification). Abbreviations: CTR – Control, CM – Conditioned medium. 
 
 HK-2 cells and HKC-8 cells treated with CM showed decreased cell growth and 
proliferation rates (Figure 33A-B). These findings might be due to increased number of 
senescent cells (Figure 34A), probably owing to acidic pH and low concentration nutrients 
available in CM. On the other hand, TP53 decreased expression was depicted in both cell 
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lines (Figure 33C) and an increase in EMT markers, including CDH2 in both cell lines and 
CD44 in HK2 cells only, was observed (Figure 34B). Notwithstanding, the lack of effect in 
cell migration (Figure 33D and Supplementary Figure 1C), significantly increased cell 
invasion was demonstrated in both normal cell lines (Figure 33E). Thus, normal cell lines 
exposed to tumor cells’ CM exhibited identical alterations to those induced by lactate 
treatment. 
  
 
Figure 33. CM promotes cell aggressiveness in normal kidney cell lines contributing to tumor 
transformation. Effect of conditioned medium from tumor cells in normal kidney cell lines at cell growth (A) by 
MTT assay, cell proliferation (B) by BrdU assay, TP53 expression (C) by RT-qPCR, cell migration (D) by wound-
healing assay and cell invasion (E) by Matrigel Invasion Chambers. *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001 compared to control; results are representative of four independent experiments with mean±SD, 
each of them in triplicates. Abbreviations: CTR – Control, CM – Conditioned medium. 
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Figure 34. CM effect on Senescence and EMT markers in normal kidney cell lines. (A) Expression of 
senescence markers (CDKN1A, GLB1and LMNB1) in normal kidney cell lines after treatment with conditioned 
medium from tumor cells, by RT-qPCR. (B) Expression of mesenchymal marker CDH2 and related-invasion cell 
marker CD44 in normal kidney cell lines after treatment with conditioned medium from tumor cells, by RT-qPCR; 
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared to control; results are representative of four 
independent experiments with mean±SD, each of them in triplicates. Abbreviations: CTR – Control, CM – 
Conditioned medium. 
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TREATMENT WITH NICOTINAMIDE AND ALPHA-CYANO-4-HYDROXYCINNAMATE 
EMULATES THE EFFECT OF LACTATE IN KIDNEY CELLS 
Nicotinamide treatment mimics lactate effect in sirtuins expression and promotes 
cell aggressiveness 
 The effect of SIRTs downregulation in cell phenotype was also tested by treating 
cells with NAM, a SIRTs activity inhibitor. 
 Globally, NAM treatment overlapped the effect of lactate in RCC cells, associating 
with decreased SIRTs protein and activity (Figure 35 A-C and Supplementary Figure 3), 
and subsequent increased histone acetylation levels (Figure 35D and Supplementary 
Figure 4). Nevertheless, NAM did not induce significant changes in cell growth and 
proliferation rates (Figure 35E-F). Moreover, a significant increase in cell migration was 
observed after NAM treatment in all studied cell lines (Figure 35G and Supplementary 
Figure 5). 
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Figure 35. NAM (200µM) mimics lactate effect in kidney cell lines. Characterization of SIRT1, SIRT3 
and SIRT6 expression by RT-qPCR (A) and western blot (B), and of sirtuins activity (C). Characterization of 
global histone acetylation of histone H3 and H4, and specific histone markers, H3K9 and H4K16 (D) by western 
blot. Effect at cell growth (E) by MTT assay, cell proliferation (F) by BrdU assay and cell migration (G) by wound-
healing assay. Results are compared to control and representative of four independent experiments with 
mean±SD, each of them in triplicates. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Abbreviations: C – 
Control, CTR – Control, N – NAM 200µM, NAM – Nicotinamide. 
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Alpha-cyano-4-hydroxycinnamate blocks lactate transport reversing the effect on 
sirtuins expression and decreases cell aggressiveness 
 To revert the effects of lactate, kidney cell lines were treated with CHC which 
prevents lactate transport into cells. Cells were treated with different concentrations of CHC 
(1, 2.5, 5, 10 and 15mM) for 48h, and the IC50 values were calculated (Supplementary 
Figure 6).  
 CHC reverted the effects of lactate, causing increased SIRTs expression (Figure 
36A-B and Supplementary Figure 7), although no significant alteration was observed in 
SIRTs activity (Figure 36C). Accordingly, decreased histone acetylation levels were 
observed (Figure 36D and Supplementary Figure 8). Furthermore, CHC exposure 
associated with cell growth decrease (Figure 36E), whereas no significant alterations were 
found in cell proliferation (Figure 36F). Except for HKC-8 cell line, CHC treatment decreased 
cells’ migration capacity (Figure 36G and Supplementary Figure 9). 
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Figure 36. CHC reverts lactate effect in kidney cell lines. Characterization of SIRT1, SIRT3 and SIRT6 
expression by RT-qPCR (A) and Western Blot (B), and of sirtuins activity (C). Characterization of global histone 
acetylation of histone H3 and H4, and specific histone markers, H3K9 and H4K16 (D) by western blot. Effect at 
cell growth (E) by MTT assay, cell proliferation (F) by BrdU assay and cell migration (G) by wound-healing 
assay. Results are compared to control and representative of four independent experiments with mean±SD, 
each of them in triplicates. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Abbreviations: CTR – Control, 
CHC – Alpha-cyano-4-hydroxycinnamate, Lac – Lactate.  
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HIF-1, SIRT1 AND SIRT6 PROTEIN LEVELS IN PRIMARY TUMORS 
 The proportion of cases defined as “positive” and immunoexpression intensity score 
were compared between normal kidney and RCC tissues for HIF-1, SIRT1 and SIRT6. 
Only nuclear expression was considered (Figure 37A).  
 As expected, a statistically significant increase (p<0.001) in HIF-1 was apparent in 
ccRCC and pRCC [72.5% (29/40) and 75% (30/40), respectively] compared to normal 
kidney tissues (3.3% [1/30]) (Figure 37B and Table 7). Concerning immunoexpression 
intensity score, RCC showed mostly high scores (+2 and +3), whereas normal tissues often 
display the lowest score (+1) (Figure 372C). Regarding pRCC, no significant differences 
were found for HIF-1 positivity between Type I and II [91.7% (11/12) and 67.9% (19/28), 
respectively] (Table 8). 
 
 
Figure 37. Characterization of HIF-1α and SIRTs in kidney tissues. Expression of HIF-1α, SIRT1 and SIRT6 
in normal kidney and renal cell carcinoma tissues (ccRCC and pRCC cases) by immunohistochemistry. 
Representative immunohistochemistry images for lower and highest intensity scores for each group of protein 
expression (A). Graphical representation of positive and negative cases (B) and immunoexpression intensity 
scores (C). Abbreviations: ccRCC – Clear cell renal cell carcinoma, pRCC – Papillary renal cell carcinoma. 
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Table 7. Protein expression of HIF-1α, SIRT1 and SIRT6 in normal kidney and RCC tissues. 
  Normal Kidney ccRCC pRCC 
HIF-1 
n 30 40 40 
Negative (%) 29 (96.7) 11 (27.5) 10 (25.0) 
Positive (%) 1 (3.3) 29 (72.5) 30 (75.0) 
 p value n.a. < 0.0001 < 0.0001 
SIRT1 
n 30 40 40 
Negative (%) 1 (3.3) 13 (32.5) 7 (17.9) 
Positive (%) 29 (97.7) 27 (67.5) 32 (82.1) 
 p value n.a. 0.0024 0.1254 
SIRT6 
n 30 40 40 
Negative (%) 3 (10.0) 17 (42.5) 23 (42.5) 
Positive (%) 27 (90.0) 23 (57.5) 17 (42.5) 
 p value n.a. 0.0425 < 0.0001 
ccRCC – Clear cell Renal Cell Carcinoma; pRCC – Papillary Renal Cell Carcinoma 
 
Table 8. Protein expression of HIF-1α, SIRT1 and SIRT6 in pRCC Type I and II cases. 
  pRCC Type I pRCC Type II 
HIF-1 
n 12 28 
Negative (%) 1 (8.3) 9 (32.1) 
Positive (%) 11 (91.7) 19 (67.9) 
 p value 0.2307 
SIRT1 
n 12 27 
Negative (%) 0 (0) 7 (25.9) 
Positive (%) 12 (100) 20 (74.1) 
 p value 0.0775 
SIRT6 
n 12 28 
Negative (%) 4 (33.3) 19 (67.9) 
Positive (%) 8 (66.7) 9 (32.1) 
 p value 0.0794 
pRCC – Papillary Renal Cell Carcinoma  
 
 Regarding SIRT1 and SIRT6, decreased expression levels were found in RCC 
compared to normal tissues, being more remarkable for SIRT6, both for percentage of 
positive cases and intensity score (Figure 37B-C). Indeed, 97.7% (29/30) of normal tissues 
displayed SIRT1 positivity, whereas ccRCC and pRCC showed positivity in 67.5% (27/40) 
and 82.1% (32/40) cases, respectively (Figure 37B). Nonetheless, significant differences 
were only observed between ccRCC compared with normal kidney (p=0.0024) (Table 7). 
SIRT6 expression was also significantly higher in normal kidney compared to ccRCC 
(p=0.0425) and pRCC (p<0.001) [90% (27/30) vs 57.5% (23/40) vs 42.5% (17/40), 
respectively] (Figure 37B and Table 7). 
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 Concerning intensity score, 50% of normal cases displayed the highest score (+3) 
for SIRT1, followed by 46% in pRCC and 17% in ccRCC cases. These differences were 
more striking for SIRT6, once 80% of normal cases display +2 or +3 scores in comparison 
with RCC, which presented the highest percentage of cases have +1 score (75% in ccRCC 
and 82% in pRCC) (Figure 37C). Additionally, pRCC Type I showed higher SIRT1 and 
SIRT6 positivity rates when compared with pRCC Type II [100% (12/12) vs 74.1% (20/27) 
and 66.7% (8/12) vs 32.1% (9/28), respectively], however without statistical significance 
(Table 8). Finally, no inverse correlation was observed between HIF-1 and SIRTs protein 
levels (p>0.05; Table 9).  
  
Table 9. Associations between HIF-1α and SIRTs in kidney tissues. 
  HIF-1  
  Negative Positive p value 
SIRT1 
n 48 60  
Negative (%) 10 (9.3) 11 (10.2) 0.8092 
Positive (%) 38 (35.2) 49 (45.4)  
SIRT6 
n 48 60  
Negative (%) 17 (15.7) 24 (22.2) 0.6921 
Positive (%) 31 (28.7) 36 (33.3)  
 
  
  
 
 
 
 
 
 
 
 
DISCUSSION 
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 Highly glycolytic tumors, including ccRCC and pRCC, are characterized by 
increased lactate production due to metabolic reprogramming [171]. The excess lactate 
conveyed to the tumor microenvironment has a relevant impact in tumor biology, 
contributing to tumor growth and therapy resistance [172-174]. The interplay between tumor 
metabolites and epigenetic landscape has recently emerged, indicating that metabolism is 
closely associated with altered epigenetics in cancer cells [93, 143]. Recently, two studies 
demonstrated the effects of lactate in modulation of epigenetic mechanisms, specifically in 
inhibition of HDACs Class I and Class II activity in colorectal and cervical cancer models 
[145, 146]. These results prompted us to investigate the interaction between metabolism 
and epigenetics in RCC. 
 We evaluated the effects of lactate in epigenetic enzymes and consequent 
alterations in RCC phenotype. Although previous studies reported the regulation of HDAC 
Class I and II by lactate, the enzymes specifically involved were not specified [145, 146]. 
Thus, we assessed the lactate’s effect on HDAC1, HDAC2 and HDAC3 isoforms activity 
but a uniform decrease in HDACs expression was not found, suggesting that the impact in 
HDAC may differ according to cancer model. The NAD+/NADH ratio plays an important role 
in SIRTs activity. Considering the high glycolytic rate of RCC cells and high lactate levels in 
the tumor microenvironment, a decrease in NAD+/NADH is expected, entailing SIRTs 
activity inhibition [60, 175, 176]. Thus, a role for lactate in SIRTs inhibition was 
hypothesized. Interestingly, we found that increased lactate decreases SIRTs expression 
and activity in RCC cell lines, specifically affecting SIRT1, SIRT3 and SIRT6, which are 
involved in metabolism reprograming [136, 177] and were shown to be downregulated in 
RCC [135]. 
 Since SIRTs, namely SIRT1, SIRT3 and SIRT6 target H3K9 and H4K16 [178-180], 
we evaluated the global histone acetylation levels and the specific histone marks in cell 
lines exposed to lactate. As expected, lactate demonstrated a reversible effect in histone 
deacetylation levels and induced histone hyperacetylation in in vitro conditions, putatively 
as consequence of SIRTs inhibition. We also observed a more striking increase in global 
H3 acetylation, and specifically in H3K9ac histone mark, than global H4 acetylation and 
H4K16ac histone mark. These findings suggest that hyperacetylation of histone H3 and 
H3K9 might be involved in gene transcription regulation. Accordingly, it was previously 
shown that lactate increases H3K9ac and H4K16ac histone marks, as well as global histone 
acetylation [145]. 
 SIRTs are involved in gene transcription regulation since an increase in acetylation 
levels caused by SIRT1 and SIRT6 downregulation leads to HIF-1 activation [137, 138]. 
Additionally, SIRT3 is an important regulator of mitochondrial oxidative stress [181], and a 
decrease in SIRT3 leads to increased ROS levels, causing HIF-1 stabilization [139]. 
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Consequently, a decrease in SIRTs levels promotes transcription of glycolytic genes and 
increases aerobic glycolysis (Warburg effect) by HIF-1 pathway activation [182]. 
Remarkably, we confirmed this inverse correlation between HIF-1 and SIRTs in RCC cells 
exposed to lactate. Likewise, those cells displayed an increase in cell membrane MCT1 and 
MCT4 expression in cell membrane, probably through a HIF-1-dependent mechanism, 
already described in other tumor models [183, 184].These findings strongly suggest that 
lactate uptake by tumor cells leads to SIRTs inhibition and subsequent increase in 
acetylation, that can promote gene transcriptional deregulation associated to increased 
glycolytic metabolism. This metabolic cooperation may explain the observed increase in 
MCT1 and MCT4 expression, since MCT1 and MCT4 are essential for lactate uptake and 
export from glycolytic cells, respectively [185]. Interestingly, an increase in MCT1 nuclear 
expression was also found, a finding that has been previously reported in soft tissue 
sarcomas [186]. Another study reported MCT1 expression in nuclear membrane of 
leucocytes, suggesting that MCT1 may facilitate transport of other carboxylic acids to the 
nucleus, in addition to lactic acid [187]. 
 Previous studies reported that SIRT1, SIRT3 and SIRT6 repress HIF-1α-induced 
glycolytic target genes [136]. However, only SIRT1 was associated with tumor growth and 
angiogenesis inhibition by deacetylating and repressing HIF-1α [137]. Moreover, SIRT1 role 
in suppressing EMT and metastases inhibition by deacetylating SMAD4 and repressing the 
effect of TGF-β signaling on MMP7 has been reported [188, 189]. Taking in account our 
results and previous findings, SIRT1 inhibition might have an important role in tumor 
progression. 
 In cervical cancer, lactate inhibits HDAC activity and increases H3 and H4 
acetylation levels, modulating cellular DNA damage repair processes and being involved in 
therapy response [146]. This suggests HDACs regulation by lactate and consequent 
involvement in gene transcription control, which may contribute to tumor progression and 
therapy resistance. In our study, albeit lactate did not affect cell growth/proliferation, it 
increased cell migration and cell invasion. Although results of EMT-related gene expression 
evaluation were not conclusive, an increase in CD44, CDH2 and MMP10 gene expression 
was observed in ccRCC cells derived from primary tumor (769-P) but not from metastatic 
ccRCC (Caki-1), which can be related to lactate ‘s role on tumor progression. These findings 
are supported by previous studies that verified an increase in cell aggressiveness 
associated with SIRTs downregulation [188, 190, 191]. In this vein, our results demonstrate 
that lactate is a tumor metabolite playing an important role in histone acetylation regulation, 
with impact in gene transcription and contributing to tumor aggressiveness and cell 
transformation. 
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 Lactate produced and exported by tumor cells can be used by other cells in the 
tumor microenvironment, including endothelial cells and stromal cancer-associated 
fibroblasts, reprogramming their functions and contributing to tumor progression [192, 193]. 
Consequently, we hypothesized that lactate might also modulate the same epigenetic 
mechanisms in adjacent normal cells. We found that exposure of normal kidney cell lines 
to lactate and to CM of tumor cells entails cellular alterations similar to those observed in 
tumor cells. Veritably, lactate uptake induces a decrease in SIRT1 expression, contributing 
to global hyperacetylation and, consequently, increased cell aggressiveness. Thus, 
lactate’s excess present in tumor microenvironment may modulate epigenetic mechanisms 
of adjacent normal cells and, eventually, contribute to the acquisition of malignant features 
in those cells, a phenomenon that might be referred to as “pseudo-transformation”.  
 The effects of lactate in renal cells were confirmed through treatment with SIRTs 
and MCTs inhibitors (NAM and CHC, respectively). NAM is a noncompetitive inhibitor that 
blocks SIRTs deacetylation activity through interaction with a catalytic intermediate 
promoting a base-exchange reaction [194-196]. SIRTs inhibitors have been proposed as 
anticancer agents, since SIRTs appear to play an important role in carcinogenesis [197]. 
NAM disclosed anti-neoplastic role in leukemia, oral squamous cell carcinoma and prostate 
cancer, decreasing cell viability and proliferation, and inducing apoptosis [198-200]. 
Nonetheless, in our study, NAM exposure mimicked the effects of lactate and CM, 
suggesting that SIRTs inhibition may contribute to increased malignant cell aggressiveness, 
promoting tumor progression. Interestingly, CHC, a classical MCTs inhibitor with more 
affinity for MCT1 [201], led to an increase in SIRTs expression, which is associated with 
decreased histone acetylation, and decreased cell migration of tumor and normal kidney 
cell lines. Preventing lactate uptake, CHC was able to revert SIRTs inhibition and attenuate 
the malignant phenotype. Because CHC also inhibits lactate efflux with consequent 
reduction on glycolytic metabolism [202], influencing NAD+ availability [176], it allows for 
SIRTs reactivation. Indeed, several in vitro and in vivo studies highlighted the role of MCT 
inhibitors in cancer [203]. Moreover, CHC potential for attenuating cancer cell 
aggressiveness was validated in glioma and breast cancer cell lines, decreasing cell 
viability, proliferation, migration and invasion [201, 204]. 
 A partial validation of in vitro findings was accomplished through the assessment of 
HIF-1, SIRT1 and SIRT6 expression in primary RCC and normal renal tissues using IHC. 
As expected, normal tissues disclosed lower HIF-1 expression compared to tumors. 
Previous studies have shown higher HIF-1 levels in ccRCC compared with other major 
RCC subtypes [205, 206], but our results did not reveal a difference between ccRCC and 
pRCC, in agreement with other studies [207]. Higher HIF-1 expression would be expected 
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in ccRCC, owing to frequent VHL inactivation, which is characteristic of this subtype, but 
HIF-1 may also be activated by FH inactivation, which occur in pRCC [208]. Regarding 
SIRTs, decreased SIRT1 and SIRT6 expression was observed in RCC compared to normal 
tissues, in line with in vitro findings and supporting the importance of some SIRTs as RCC 
tumor suppressors. Furthermore, our results are in accordance with a recent study that also 
disclosed SIRT1, SIRT3 and SIRT6 downregulation in RCC [135]. Also an inverse 
correlation between HIF-1 and SIRTs protein levels was unveiled in our study, confirming 
previous findings, which also disclosed that SIRT6 inhibited RCC progression through 
inhibition of HIF-1 expression [209]. 
 Globally, our data suggest a new mechanism by which lactate contributes to RCC 
aggressiveness and pseudo-transformation adjacent normal cells by a SIRTs-mediated 
mechanism. Lactate produced by glycolytic tumor cells is exported across the cell 
membrane to the tumor microenvironment by MCTs and may be used by other tumor and 
adjacent normal cells through a NAD+-depended pathway, leading to decreased 
NAD+/NADH ratio, resulting in SIRTs inhibition. This, in turn, increases histone H3 and H4 
hyperacetylation with consequent HIF-1 activation increasing glycolytic metabolism and 
tumor cell aggressiveness (Figure 38). 
  
 
Figure 38. Lactate modulation of SIRTs expression in RCC. Lactate present in tumor microenvironment 
inhibits Sirtuins activity by NAD+-dependent pathway and increases cell aggressiveness in tumor and normal 
adjacent cells via HIF activation. Abbreviations: GLUT – Glucose transporter, HIF – Hypoxia-inducible factor, 
LDH – Lactate dehydrogenase, MCT – Monocarboxylate transporter, NAD – Nicotinamide adenine dinucleotide, 
ROS – Reactive oxygen species, SIRT – Sirtuin, TCA – Tricarboxylic acid cycle. Lameirinhas A. unpublished. 
 
 Currently, partial or radical nephrectomy are gold standard treatments for RCC 
patients [42]. Additionally, cytokines, such as interferon-alfa and IL-2, have been used for 
treatment of metastatic disease, however with low long-term efficacy [45]. Over the last 
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decade, new targeted therapies for RCC management have been developed [47] and 
several clinical trials demonstrated significant improvements in response rates with 
inclusion of tyrosine kinase inhibitors, mTOR inhibitors, antiangiogenic agents and immune 
checkpoint inhibitors [46]. Nevertheless, new advances are still needed as those treatments 
are not curative. Considering our findings, especially the role of lactate in tumor 
microenvironment modulation, new therapeutic strategies for advanced RCC might be 
envisaged. Indeed, the use of MCTs inhibitors or other drugs that restore SIRTs activity 
(e.g., resveratrol) should be explored, to complement current therapies, improving RCC 
patients’ outcome [197, 210]. 
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 We have shown that, in RCC, lactate contributes to enhance tumor cell 
aggressiveness, by SIRTs’ activity reduction. Furthermore, through its increased levels in 
tumor microenvironment, it also has an impact in normal cells, modulating their phenotype 
and bringing they closer to that of malignant cells (pseudo-transformation). Thus, tumor 
metabolism was unveiled to be a putative and promising therapeutic target in RCC, 
deserving further exploration. 
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APPENDIX I 
Supplementary figures 
 
Supplementary Figure 1. Representative pictures for migratory capacity of tumor (A) and normal (B) kidney 
cell lines exposed to 20mM lactate, and normal kidney cells exposed to conditioned medium of tumor cells (C). 
Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 (40x magnification) 
Abbreviations: CM – Conditioned medium, CTR – Control, Lac – Lactate. 
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Supplementary Figure 2. Lactate and Glucose characterization in CM. Quantification of lactate (A) and 
glucose (B) present in conditioned mediums of kidney tumor cells after 24h, 48h and 72h of culture. 
Abbreviations: CM – Conditioned medium. 
 
 
Supplementary Figure 3. Characterization of SIRT1, SIRT3 and SIRT6 expression in kidney cell lines treated 
with 200µM NAM by immunofluorescence. Photograph taken in microscope Olympus IX51 with a digital camera 
Olympus XM10 (200x magnification). Abbreviations: CTR – Control, NAM – Nicotinamide. 
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Supplementary Figure 4. Characterization of total Acetylated Lysine (A), global histone acetylation of histone 
H3 and H4 (B), and specific histone markers, H3K9 and H4K16 (C), in kidney cell lines treated with 200µM 
NAM, by immunofluorescence. Photograph taken in microscope Olympus IX51 with a digital camera Olympus 
XM10 (200x magnification). Abbreviations: CTR – Control, NAM– Nicotinamide. 
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Supplementary Figure 5. Representative pictures for migratory capacity of kidney cell lines exposed to 200µM 
NAM. Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 (40x magnification) 
Abbreviations: CTR – Control, NAM– Nicotinamide. 
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Supplementary Figure 6. Growth inhibition by CHC. Cell viability curves after 48h of CHC treatment (1, 2.5, 
5, 10 and 15mM) (A) and IC50 values (mean±SD) (B) for kidney cell lines. Abbreviations: CHC– Alpha-cyano-4-
hydroxycinnamate. 
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Supplementary Figure 7. Characterization of SIRT1, SIRT3 and SIRT6 expression in kidney cell lines treated 
with CHC + 20mM Lac by immunofluorescence. Photograph taken in microscope Olympus IX51 with a digital 
camera Olympus XM10 (200x magnification). Abbreviations: CHC– Alpha-cyano-4-hydroxycinnamate, CTR – 
Control, Lac – Lactate 
. 
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Supplementary Figure 8. Characterization of total Acetylated Lysine (A), global histone acetylation of histone 
H3 and H4 (B), and specific histone markers, H3K9 and H4K16 (C), in kidney cell lines treated with CHC + 
20mM Lac, by immunofluorescence. Photograph taken in microscope Olympus IX51 with a digital camera 
Olympus XM10 (200x magnification). Abbreviations: CHC– Alpha-cyano-4-hydroxycinnamate, CTR – Control, 
Lac – Lactate. 
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Supplementary Figure 9. Representative pictures for migratory capacity of kidney cell lines exposed to CHC 
and CHC + 20mM Lac. Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 
(40x magnification) Abbreviations: CHC– Alpha-cyano-4-hydroxycinnamate, CTR – Control, Lac – Lactate. 
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APPENDIX II 
Supplementary data 
 
Supplementary Figure 10. Morphological phenotype of kidney cell lines after treatment. Morphological 
alterations in 6 kidney cell lines after treatment with 10 and 20mM Lac (A), CM (B), 200µM NAM  (C), CHC and 
CHC + 20mM Lac (D). Photograph taken in microscope Olympus IX51 with a digital camera Olympus XM10 
(200x magnification). Abbreviations: CHC– Alpha-cyano-4-hydroxycinnamate, CM – Conditioned medium, CTR 
– Control, Lac – Lactate, NAM – Nicotinamide. 
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Supplementary Figure 11. Metabolic characterization of kidney cell lines after treatment. Glucose 
consumption and lactate production quantification after treatment with 10 and 20mM Lac (A), CM (B), CHC and 
CHC + 20mM Lac (C). Abbreviations: CHC– Alpha-cyano-4-hydroxycinnamate, CM – Conditioned medium, 
CTR – Control, Lac – Lactate. 
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APPENDIX III 
Kidney cell lines characterization 
Expression of MCT1, MCT4, VHL and HIF-1 kidney cell line 
 MTCs, VHL and HIF-1 characterization in kidney cell lines was evaluated by RT-
qPCR and ICC. Additionally, qMSP was performed to detect MCTs and VHL promoter 
methylation levels.  
 The studied cell lines expressed distinct levels of MCT1 (Supplementary Figure 
12A), and a conspicuous MCT1 plasma membrane expression was observed in non-
malignant kidney (HKC-8) cell line and ccRCC cell lines, 769-P and Caki-1 (Supplementary 
Figure 12D). MCT1 expression was also present in the cytoplasm and in the nucleus. 
Accordingly, no methylation levels were found in MCT1 promoter.  
 In contrast, excepting ACHN, all cell lines expressed MCT4 (Supplementary Figure 
12B) although aberrant methylation was detected in respective promoter (Supplementary 
Figure 12C). Moreover, although this protein was mostly found in plasma membrane, MCT4 
was also present in cytoplasm at lower expression (Supplementary Figure 12D).  
 
 
Supplementary Figure 12. MCTs characterization in kidney cell lines. Characterization of MCT1 (A) and 
MCT4 (B) expression in 6 kidney cell lines by RT-qPCR. Quantification of MCT4 promoter methylation levels by 
qMSP (C). Characterization of MCT1 and MCT4 protein expression and localization immunocytochemistry (D). 
Photograph taken in microscope Olympus BX41 with a digital camera Olympus U-TV0.63XC (200x 
magnification). 
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 Regarding VHL, the ccRCC primary cell line (769-P) was the only tested cell line 
that did not show VHL expression (Supplementary Figure 13A), whereas respective 
promoter was found to be methylated (Supplementary Figure 13C). Despite Caki-2 cells 
showed positive mRNA levels, no VHL protein expression was observed in ICC. In the 
remaining cell lines, VHL was expressed at nucleus and cytoplasm. Concerning ICC 
analysis, 769-P was negative for HIF-1, whereas Caki-2 cells present the highest nuclear 
protein expression (Supplementary Figure 13D). Reduced HIF-1 expression was found 
with in nucleus and cytoplasm of the remaining tumor cell lines, as well as in normal kidney 
cells (Supplementary Figure 13D). Importantly, these results agree with those described in 
the literature.  
 
 
Supplementary Figure 13. VHL and HIF-1 characterization in kidney cell lines. Characterization of VHL 
(A) and HIF-1 (B) expression in 6 kidney cell lines by RT-qPCR. Quantification of VHL promoter methylation 
levels by qMSP (C). Characterization of VHL and HIF-1 protein expression and localization 
immunocytochemistry (D). Photograph taken in microscope Olympus BX41 with a digital camera Olympus U-
TV0.63XC (200x magnification). 
 
Kidney cell lines metabolic characterization 
 Extracellular glucose and lactate levels were quantified, and the lactate/glucose 
ratios were determined for kidney cell lines. In Supplementary Figure 14A at 48h, the HKC-
8 cell line consumed the majority of available glucose in the culture medium, with an 
average consumption of 1.98g/L. Additionally, 769-P and ACHN cells showed a similar 
glucose consumption levels, approximately 1.75g/L. The Caki-1 and Caki-2 tumor cells also 
showed high glucose consumption, approximately 1.5g/L. In contrast, the normal kidney 
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cell line HK-2 only wasted half of available glucose, about 1g/L. Regarding lactate 
production (Supplementary Figure 14B), HK-2 cells produced about 10mM at 48h. The 
normal cell line HKC-8 and the two ccRCC lines (769-P and Caki-1) showed a slightly higher 
production of 12mM of lactate. Finally, Caki-2 and ACHN pRCC cell lines produced the 
highest lactate levels (15mM).  
 The lactate/glucose ratio was calculated by dividing the concentration of lactate 
produced (mM) by the concentration of glucose consumed (mM). Supplementary Figure 
14C showed that the normal cell lines (HKC-8 and HK-2) presented a low lactate/glucose 
ratio of approximately 1, which is characteristic of non-glycolytic cells. In contrast, all tumor 
cell lines displayed a high lactate/glucose ratio (approximately 2), that usually is found in 
glycolytic cells due to Warburg effect.    
 
 
Supplementary Figure 14. Metabolic characterization of kidney cell lines. Glucose consumption (A) and 
lactate production (B) quantification, and calculation of glycolytic rates (C) of 6 kidney cell lines, after 48h of 
culture 
 
